https://trial.medpath.com/news/viatris-announces-publication-of-phase-2b-care-study-data-for-cenerimod-in-lancet-rheumatology 2024-12-18T12:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/positive-results-advance-peanut-tablet-to-phase-ii-development-globenewswire 2024-12-18T12:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/fred-hutchinson-biostatistician-pioneers-novel-approaches-in-cancer-clinical-trial-design 2024-12-18T12:00:02+00:00 weekly 0.7 https://trial.medpath.com/news/gan-lee-s-novel-glp-1-drug-gets-fda-green-light-for-head-to-head-trial-against-eli 2024-12-18T11:18:57+00:00 weekly 0.7 https://trial.medpath.com/news/biopharma-s-manufacturing-push-and-other-2024-trends-biospace-iheart 2024-12-18T11:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/further-research-on-balloon-guide-catheters-required-following-inconclusive-protect-mt-results 2024-12-18T11:04:13+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-submits-application-to-the-european-medicines-agency-seeking-biospace 2024-12-18T10:53:02+00:00 weekly 0.7 https://trial.medpath.com/news/patient-navigation-services-evolve-in-oncology-care-new-cms-codes-and-implementation-challenges-discussed-at-pcoc-2024 2024-12-18T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/egyptian-drug-authority-approves-lilly-and-eva-s-insulin-injection-yahoo-finance 2024-12-18T09:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/nccn-reports-progress-in-cancer-care-access-despite-ongoing-drug-shortage-challenges 2024-12-18T08:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/financial-toxicity-remains-major-barrier-in-cancer-care-despite-improved-patient-experience 2024-12-18T08:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/oncology-clinical-pathways-need-rapid-updates-to-keep-pace-with-treatment-innovation 2024-12-18T08:18:00+00:00 weekly 0.7 https://trial.medpath.com/news/applied-dna-customer-uhkt-initiates-phase-i-clinical-trial-of-uhkt-car123-01 2024-12-18T08:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/oncology-pharmacists-expand-clinical-roles-push-for-provider-status-recognition 2024-12-18T08:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-antimicrobial-technology-with-unrivalled-efficacy-poised-to-revolutionise-global 2024-12-18T08:06:07+00:00 weekly 0.7 https://trial.medpath.com/news/vancouver-biotech-briacell-to-raise-us-5-5-million-in-share-offering 2024-12-18T08:03:12+00:00 weekly 0.7 https://trial.medpath.com/news/scynexis-initiates-dosing-in-phase-1-trial-of-scy-247-for-invasive-fungal-infections 2024-12-18T08:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/jenavalve-announces-first-case-in-new-heart-valve-registry-massdevice 2024-12-18T07:52:00+00:00 weekly 0.7 https://trial.medpath.com/news/thermo-fisher-scientific-and-eversana-partner-to-advance-ngs-based-precision-medicine-in-blood-cancers 2024-12-18T07:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/scipher-medicine-expands-precision-medicine-partnerships-to-transform-rheumatoid-arthritis-treatment 2024-12-18T06:37:44+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-alzheimer-s-treatment-kisunla-secures-fourth-major-market-approval-with-nmpa 2024-12-18T05:59:09+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-teva-say-study-results-show-gut-disease-drug-could-be-best-in-class 2024-12-18T05:28:35+00:00 weekly 0.7 https://trial.medpath.com/news/actuate-sees-37-cut-in-risk-of-death-in-phase-ii-pancreatic-cancer-trial 2024-12-18T05:28:13+00:00 weekly 0.7 https://trial.medpath.com/news/oneoncology-cmo-emphasizes-critical-role-of-real-world-evidence-in-precision-medicine-testing 2024-12-18T04:36:00+00:00 weekly 0.7 https://trial.medpath.com/news/oncology-leaders-highlight-growing-challenges-in-managing-cancer-treatment-data 2024-12-18T04:35:00+00:00 weekly 0.7 https://trial.medpath.com/news/ira-implementation-reshapes-cancer-drug-development-and-access-landscape 2024-12-18T04:29:00+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-grants-orphan-medicinal-product-designation-to-agios-mitapivat-for-sickle-cell-disease 2024-12-18T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-enters-obesity-market-with-112m-deal-for-hansoh-s-oral-glp-1-drug 2024-12-18T03:59:34+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-evolution-in-2025-strengthening-site-patient-relationships-through-technology 2024-12-18T03:01:35+00:00 weekly 0.7 https://trial.medpath.com/news/lipocine-inc-filed-sec-form-8-k-other-events-financial-statements-and-exhibits 2024-12-18T02:40:54+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-resistance-to-paxlovid-is-uncommon-cidrap 2024-12-18T02:31:51+00:00 weekly 0.7 https://trial.medpath.com/news/eyedna-therapeutics-receives-fda-rare-pediatric-disease-designation-for-hora-pde6b 2024-12-18T00:38:13+00:00 weekly 0.7 https://trial.medpath.com/news/startup-siteone-secures-100m-to-forge-ahead-with-novel-non-opioid-pain-meds 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-shares-surge-following-positive-mid-stage-study-results 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-gilead-s-trodelvy-for-lung-cancer-treatment 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ucsf-led-study-advances-understanding-and-treatment-of-hidradenitis-suppurativa 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/noema-pharma-appoints-volker-knappertz-m-d-as-executive-vice-president-of-research-development 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/medera-s-novoheart-partners-with-curi-bio-to-revolutionize-human-based-cardiac-drug-screening 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alpha-tau-to-present-new-data-at-2025-asco-gi-symposium-and-host-r-d-update-day 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/retina-top-items-in-ophthalmology-for-2024 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alzamend-neuro-to-present-non-clinical-data-on-al001-at-society-of-toxicology-2025 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/percheron-therapeutics-reports-resuls-from-phase-iib-study-of-avicursen 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/teva-and-sanofi-jump-on-experimental-bowel-disease-drug-success-yahoo-finance 2024-12-17T21:49:01+00:00 weekly 0.7 https://trial.medpath.com/news/research-spotlight-pancreatic-cancer-a-look-back-at-2024 2024-12-17T21:31:52+00:00 weekly 0.7 https://trial.medpath.com/news/structure-therapeutics-unveils-breakthrough-oral-obesity-drug-first-in-class-amylin 2024-12-17T21:19:58+00:00 weekly 0.7 https://trial.medpath.com/news/partnership-advances-targeted-therapies-for-blood-cancers-newswise 2024-12-17T20:49:05+00:00 weekly 0.7 https://trial.medpath.com/news/asco-reading-room-sc-vs-iv-trastuzumab-pertuzumab-a-time-and-motion-substudy-of 2024-12-17T20:21:50+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-announces-idmc-recommendation-of-move-forward-dose-in-part-2a-of-pr-newswire 2024-12-17T20:05:21+00:00 weekly 0.7 https://trial.medpath.com/news/177lu-dotatate-is-a-viable-treatment-in-meningioma-targeted-oncology 2024-12-17T20:03:24+00:00 weekly 0.7 https://trial.medpath.com/news/pulmonary-sarcoidosis-treatment-efzofitimod-phase-3-trial-to-go-on 2024-12-17T19:38:26+00:00 weekly 0.7 https://trial.medpath.com/news/precision-treatment-for-alzheimer-s-disease-reduces-phosphorylated-tau-mdlinx 2024-12-17T19:25:30+00:00 weekly 0.7 https://trial.medpath.com/news/ondine-commencing-us-phase-3-clinical-trial-webdisclosure 2024-12-17T19:15:45+00:00 weekly 0.7 https://trial.medpath.com/news/biocardia-launches-revolutionary-morph-dna-steerable-introducer-advances-stock-titan 2024-12-17T19:14:28+00:00 weekly 0.7 https://trial.medpath.com/news/does-medical-cannabis-have-physical-mental-health-risks-rutgers-health-kicks-off-study 2024-12-17T19:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/study-supports-role-of-ctdna-in-predicting-outcomes-in-hr-early-breast-cancer 2024-12-17T19:02:40+00:00 weekly 0.7 https://trial.medpath.com/news/adrienne-waks-on-margot-tbcrc052-phase-ii-trial-in-her2-positive-breast-cancer 2024-12-17T18:55:31+00:00 weekly 0.7 https://trial.medpath.com/news/analysts-tell-moderna-investors-to-hold-after-2024-s-steep-drop-biospace 2024-12-17T17:21:19+00:00 weekly 0.7 https://trial.medpath.com/news/merck-targets-2025-rsv-season-with-antibody-now-under-fda-review-biopharma-dive 2024-12-17T17:15:09+00:00 weekly 0.7 https://trial.medpath.com/news/neural-stem-cell-transplants-show-promise-for-spinal-injuries-neuroscience-news 2024-12-17T17:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/top-cancer-treatment-advances-at-msk-in-2024 2024-12-17T16:56:25+00:00 weekly 0.7 https://trial.medpath.com/news/muscle-stem-cell-therapy-offers-hope-for-duchenne-patients-technology-networks 2024-12-17T16:51:26+00:00 weekly 0.7 https://trial.medpath.com/news/kidney-patients-interested-and-anxious-on-xenotransplantation-clinical-trials 2024-12-17T16:50:29+00:00 weekly 0.7 https://trial.medpath.com/news/dc-circuit-affirms-fda-s-fast-track-denial-of-vanda-stomach-drug-bloomberg-law-news 2024-12-17T16:44:00+00:00 weekly 0.7 https://trial.medpath.com/news/immune-suppressing-drug-does-not-improve-covid-19-recovery-study-vumc-news 2024-12-17T15:54:10+00:00 weekly 0.7 https://trial.medpath.com/news/granules-pharmaceuticals-gains-u-s-fda-approval-for-lisdexamfetamine-dimesylate 2024-12-17T15:33:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-complete-response-letter-to-subcutaneous-amivantamab-bla-in-egfr-nsclc 2024-12-17T15:18:10+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-woman-living-healthy-with-kidney-sourced-from-pig 2024-12-17T15:12:08+00:00 weekly 0.7 https://trial.medpath.com/news/camizestrant-outperforms-fulvestrant-in-er-her2-breast-cancer 2024-12-17T15:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/menin-inhibitor-clinical-trial-puts-pediatric-leukemia-patient-in-remission 2024-12-17T15:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/parkinson-s-drug-comes-to-market-with-help-of-renowned-university-of-kansas 2024-12-17T14:49:06+00:00 weekly 0.7 https://trial.medpath.com/news/arcturus-shares-maintain-buy-rating-as-ema-nods-to-covid-19-vaccine-investing-com 2024-12-17T14:29:56+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-orphan-drug-designation-for-jaguar-health-s-crofelemer-for-treatment-of 2024-12-17T14:22:56+00:00 weekly 0.7 https://trial.medpath.com/news/sonnet-biotherapeutics-holdings-inc-reports-significant-clinical-progress-and-financial-updates-for-fiscal-year-2024 2024-12-17T14:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/psyence-biomed-highlights-recent-progress-on-active-phase-iib-clinical-trial 2024-12-17T13:51:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-status-to-gilead-s-lung-cancer-drug-investing-com 2024-12-17T13:42:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-lipocine-for-lpcn-1148-as-a-treatment-for-pr-newswire 2024-12-17T13:32:25+00:00 weekly 0.7 https://trial.medpath.com/news/indapta-therapeutics-secures-22-5-million-to-advance-clinical-trials-of-innovative-cancer 2024-12-17T13:22:58+00:00 weekly 0.7 https://trial.medpath.com/news/biomea-fusion-s-diabetes-drug-shows-breakthrough-results-in-phase-ii-trial-stock-titan 2024-12-17T13:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/abbott-announces-first-in-world-leadless-pacing-procedures-in-the-left-bundle-branch 2024-12-17T13:09:26+00:00 weekly 0.7 https://trial.medpath.com/news/mediwound-to-host-virtual-key-opinion-leader-event-to-globenewswire 2024-12-17T13:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/glyconex-announces-first-patient-dosed-in-phase-3-clinical-trial-for-denosumab-biosimilar 2024-12-17T12:53:17+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-fda-bid-for-subcutaneous-rybrevant-falls-short-biospace 2024-12-17T12:31:31+00:00 weekly 0.7 https://trial.medpath.com/news/eylea-hd-r-aflibercept-injection-8-mg-phase-3-trial-meets-globenewswire 2024-12-17T12:23:47+00:00 weekly 0.7 https://trial.medpath.com/news/teen-substance-use-hits-historic-lows-mtf-survey-shows-continued-post-pandemic-decline 2024-12-17T12:19:10+00:00 weekly 0.7 https://trial.medpath.com/news/essa-pharma-halts-key-cancer-drug-trials-initiates-strategic-review-amid-clinical-setback 2024-12-17T12:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/icymi-highlights-from-ims-2024-american-journal-of-managed-care 2024-12-17T12:03:30+00:00 weekly 0.7 https://trial.medpath.com/news/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-biospace 2024-12-17T11:23:47+00:00 weekly 0.7 https://trial.medpath.com/news/biohaven-ltd-s-strategic-advancements-and-pipeline-strengthen-buy-rating 2024-12-17T11:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/what-s-driving-biomea-fusion-stock-soars-25-markets-insider 2024-12-17T10:54:29+00:00 weekly 0.7 https://trial.medpath.com/news/ou-health-sciences-leads-clinical-trial-of-device-designed-to-induce-ovulation-in-women-with-pcos 2024-12-17T10:44:20+00:00 weekly 0.7 https://trial.medpath.com/news/corcept-therapeutics-cushing-s-syndrome-therapy-shows-promise-in-phase-iii-trial-yahoo 2024-12-17T10:22:48+00:00 weekly 0.7 https://trial.medpath.com/news/nuclear-isotopes-emerge-as-promising-tool-in-cancer-clinical-trials-despite-production-challenges 2024-12-17T10:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/esocap-publishes-positive-phase-ii-results-for-eso-101-in-treating-eosinophilic-esophagitis 2024-12-17T10:11:00+00:00 weekly 0.7 https://trial.medpath.com/news/mytomorrows-enhances-clinical-trial-platform-with-isrctn-integration-and-ai-capabilities 2024-12-17T10:05:18+00:00 weekly 0.7 https://trial.medpath.com/news/quadruplet-therapy-and-mrd-monitoring-show-promise-in-newly-diagnosed-multiple-myeloma-treatment 2024-12-17T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/exegi-pharma-reports-positive-topline-results-in-exe-346-prof-phase-1b-study 2024-12-17T09:41:00+00:00 weekly 0.7 https://trial.medpath.com/news/senders-pediatrics-seeks-young-participants-for-epstein-barr-virus-vaccine-clinical-trial 2024-12-17T09:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/butantan-institute-seeks-anvisa-approval-for-single-dose-dengue-vaccine 2024-12-17T08:47:00+00:00 weekly 0.7 https://trial.medpath.com/news/digital-training-tool-developed-to-enhance-biosimilar-switch-communication-between-prescribers-and-patients 2024-12-17T08:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/lenvatinib-plus-pembrolizumab-versus-sunitinib-in-advanced-renal-cell-carcinoma-urotoday 2024-12-17T08:20:08+00:00 weekly 0.7 https://trial.medpath.com/news/uncommon-cures-and-carexso-partner-to-expand-orphan-drug-clinical-trials-in-the-middle-east 2024-12-17T08:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/how-j-j-navigated-regulatory-approval-for-a-drug-to-watch-clarivate 2024-12-17T08:00:06+00:00 weekly 0.7 https://trial.medpath.com/news/fda-denies-full-approval-for-andexxa-following-dosing-uncertainties 2024-12-17T07:13:46+00:00 weekly 0.7 https://trial.medpath.com/news/nurix-therapeutics-btk-degrader-shows-promise-in-clinical-trials 2024-12-17T05:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/neurogene-s-gene-therapy-shows-promise-for-rett-syndrome-amid-clinical-and-market-risks 2024-12-17T04:41:00+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-pharma-s-promising-growth-prospects-buy-rating-backed-by-positive-clinical-results 2024-12-17T04:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/health-check-clinical-trials-don-t-sleigh-down-for-the-silly-season-stockhead 2024-12-17T01:49:48+00:00 weekly 0.7 https://trial.medpath.com/news/bavarian-nordic-partners-with-serum-institute-of-india-for-global-mpox-vaccine-manufacturing 2024-12-17T01:31:48+00:00 weekly 0.7 https://trial.medpath.com/news/are-you-over-18-generally-healthy-and-assigned-male-at-birth-the-reporter-uab 2024-12-17T01:22:25+00:00 weekly 0.7 https://trial.medpath.com/news/cardiofocus-announces-first-patients-treated-with-optishottm-pulsed-field-ablation-system 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/large-clinical-study-finds-home-based-virtual-reality-device-creates-greater-relief-for-high-impact-chronic-pain-patients 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biomea-fusion-s-diabetes-drug-study-shows-positive-results-despite-stock-decline 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-link-between-hearing-loss-and-cognitive-decline 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/affimed-reports-positive-clinical-update-on-afm24-atezolizumab-combination-therapy-in-non-small-cell-lung-cancer-nsclc 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lipocine-inc-advances-in-metabolic-and-endocrine-disorders-treatment 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/guangshengtang-s-innovative-hepatitis-b-drug-included-in-breakthrough-therapy-list 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biper-therapeutics-secures-eur800000-in-bridge-funding-for-gastrointestinal-cancer-treatment-development 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immuneering-to-present-data-from-three-arms-of-its-ongoing-phase-2a-trial-of-imm-1-104-in-early-january-2025 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/surgical-intervention-may-improve-survival-in-young-patients-with-breast-cancer 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-gives-crl-to-j-j-s-bla-for-subcutaneous-rybrevant-in-nsclc 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fresenius-kabi-launches-epinephrine-injection-usp-expanding 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/top-5-most-read-breast-cancer-articles-of-2024-highlight-advances-in-research-and-treatment 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-vaccine-insights-on-pregnancy-and-breastfeeding 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sagimet-biosciences-up-30-on-strong-clinical-stage-data-mugglehead-magazine 2024-12-16T23:58:55+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-update-on-neoadjuvant-therapy-trials-in-rcc 2024-12-16T23:43:00+00:00 weekly 0.7 https://trial.medpath.com/news/merus-announces-first-patient-dosed-in-phase-2-trial-of-petosemtamab-in-3l-mcrc 2024-12-16T23:42:24+00:00 weekly 0.7 https://trial.medpath.com/news/biomea-fusion-to-host-conference-call-to-announce-topline-results-from-phase-ii-covalent-111 2024-12-16T23:30:52+00:00 weekly 0.7 https://trial.medpath.com/news/biomea-fusion-to-host-conference-call-to-announce-topline-globenewswire 2024-12-16T23:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/purpose-beyond-a-cure-advancing-hodgkin-lymphoma-treatment-uf-health 2024-12-16T22:50:40+00:00 weekly 0.7 https://trial.medpath.com/news/prevail-therapeutics-seeking-to-bring-gene-therapy-pr001-to-parkinson-disease-cgtlive-r 2024-12-16T22:31:08+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-enrolled-receive-kimmtrak-in-phase-3-uveal-melanoma-trial-cure-today 2024-12-16T22:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/lehigh-valley-health-network-only-in-region-to-participate-in-drug-coated-balloon-clinical-trial 2024-12-16T22:17:49+00:00 weekly 0.7 https://trial.medpath.com/news/briacell-therapeutics-corp-sec-10-q-report-tradingview 2024-12-16T22:01:47+00:00 weekly 0.7 https://trial.medpath.com/news/merck-provides-update-on-keyvibe-and-keyform-clinical-development-programs 2024-12-16T21:34:25+00:00 weekly 0.7 https://trial.medpath.com/news/knight-therapeutics-announces-filing-of-new-drug-submission-for-qelbree-r-viloxazine-in-canada 2024-12-16T21:32:29+00:00 weekly 0.7 https://trial.medpath.com/news/contineum-therapeutics-initiates-patient-dosing-in-phase-1b-pet-trial 2024-12-16T21:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-explores-whether-cbd-can-reduce-scan-related-anxiety-in-patients-with-advanced 2024-12-16T20:57:42+00:00 weekly 0.7 https://trial.medpath.com/news/biocardia-s-swot-analysis-cell-therapy-stock-faces-pivotal-trial-phase-investing-com 2024-12-16T20:25:40+00:00 weekly 0.7 https://trial.medpath.com/news/national-trial-explores-light-therapy-for-parkinson-s-disease 2024-12-16T20:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/q32-bio-pushes-back-phase-2-trial-of-adx-097-in-aav-patients-anca-vasculitis-news 2024-12-16T19:15:15+00:00 weekly 0.7 https://trial.medpath.com/news/biohaven-reports-positive-phase-1-degrader-data-achieving-deep-targeted-igg-pr-newswire 2024-12-16T18:31:25+00:00 weekly 0.7 https://trial.medpath.com/news/tracer-to-diagnose-parkinson-s-via-pet-scans-moving-into-clinical-trial 2024-12-16T18:15:52+00:00 weekly 0.7 https://trial.medpath.com/news/findings-from-minzasolmin-proof-of-concept-orchestra-study-shape-next-steps-in-ucb 2024-12-16T18:01:28+00:00 weekly 0.7 https://trial.medpath.com/news/mark-humayun-md-phd-discusses-advance-stem-cell-derived-therapies-for-dry-amd 2024-12-16T17:13:15+00:00 weekly 0.7 https://trial.medpath.com/news/usf-health-launches-state-funded-hyperbaric-oxygen-therapy-trial-with-first-patient 2024-12-16T16:38:03+00:00 weekly 0.7 https://trial.medpath.com/news/reviva-announces-prel-topline-ole-data-of-phase-3-recover-study-of-brilaroxazine-in 2024-12-16T16:27:54+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-of-sildenafil-cream-for-fsad-maintained-across-patient-subgroups-urology-times 2024-12-16T16:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/lib-therapeutics-submits-a-biologic-license-application-to-fda-for-lerodalcibep-for-biospace 2024-12-16T16:05:59+00:00 weekly 0.7 https://trial.medpath.com/news/why-the-investor-craze-for-ozempic-and-rival-weight-loss-drugs-may-resume-next-year 2024-12-16T15:34:30+00:00 weekly 0.7 https://trial.medpath.com/news/blood-test-may-reduce-unnecessary-prostate-cancer-biopsies-news-center 2024-12-16T15:30:17+00:00 weekly 0.7 https://trial.medpath.com/news/3-closely-watched-drugs-that-failed-in-the-clinic-pharmavoice 2024-12-16T15:16:34+00:00 weekly 0.7 https://trial.medpath.com/news/neurocrine-jumps-after-snagging-fda-approval-for-a-first-in-decades-drug-yahoo 2024-12-16T15:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/arcutis-submits-snda-for-roflumilast-cream-0-05-to-fda-for-patients-ages-2-to-5-with 2024-12-16T15:00:46+00:00 weekly 0.7 https://trial.medpath.com/news/viiv-healthcare-announces-chmp-positive-opinion-for-vocabria-rekambys-the-first-and 2024-12-16T14:57:03+00:00 weekly 0.7 https://trial.medpath.com/news/genprex-s-reqorsa-advances-to-phase-2-after-successful-safety-trial-in-lung-cancer-treatment 2024-12-16T14:40:33+00:00 weekly 0.7 https://trial.medpath.com/news/dermata-receives-approval-from-fda-for-the-proprietary-name-xyngari-tm 2024-12-16T14:20:48+00:00 weekly 0.7 https://trial.medpath.com/news/novel-dll3-targeted-bites-and-b7-h3-adcs-show-promise-in-extensive-stage-sclc-treatment 2024-12-16T14:15:04+00:00 weekly 0.7 https://trial.medpath.com/news/new-insights-trial-of-transcontm-hgh-lonapegsomatropin-in-globenewswire 2024-12-16T14:04:15+00:00 weekly 0.7 https://trial.medpath.com/news/sifi-provides-updates-on-the-uk-and-us-regulatory-pathways-for-akantior-r-in-the-biospace 2024-12-16T13:57:31+00:00 weekly 0.7 https://trial.medpath.com/news/tharimmune-announces-phase-2-study-plan-for-th104-in-patients-with-moderate-to-severe 2024-12-16T13:55:28+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotech-secures-fda-rare-pediatric-disease-status-for-novel-brain-cancer-drug 2024-12-16T13:52:22+00:00 weekly 0.7 https://trial.medpath.com/news/beigene-explains-the-landscape-of-oncology-trials-in-brazil-clinical-leader 2024-12-16T13:52:18+00:00 weekly 0.7 https://trial.medpath.com/news/beta-blockers-associated-with-delayed-onset-and-decreased-progression-of-huntington-s-disease 2024-12-16T13:51:55+00:00 weekly 0.7 https://trial.medpath.com/news/mindmed-announces-first-patient-dosed-in-phase-3-voyage-study-of-mm120-in-biospace 2024-12-16T13:45:14+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-human-study-demonstrates-the-potential-of-the-reprieve-system-in-patients-with 2024-12-16T13:45:13+00:00 weekly 0.7 https://trial.medpath.com/news/histosonics-is-expanding-to-treat-pancreatic-tumors-massdevice 2024-12-16T13:27:23+00:00 weekly 0.7 https://trial.medpath.com/news/jemperli-dostarlimab-receives-us-fda-breakthrough-therapy-designation-for-locally-gsk 2024-12-16T13:15:44+00:00 weekly 0.7 https://trial.medpath.com/news/puretech-s-breakthrough-ipf-drug-shows-81-superior-efficacy-in-phase-2b-trial-results 2024-12-16T13:14:16+00:00 weekly 0.7 https://trial.medpath.com/news/pepgen-announces-clinical-hold-in-the-u-s-on-ind-application-to-initiate-connect2 2024-12-16T13:13:23+00:00 weekly 0.7 https://trial.medpath.com/news/goldman-sachs-lifts-neurocrine-bio-shares-target-buy-rating-on-fda-approval 2024-12-16T13:13:23+00:00 weekly 0.7 https://trial.medpath.com/news/windtree-announces-istaroxime-presentation-by-cardiogenic-globenewswire 2024-12-16T13:05:38+00:00 weekly 0.7 https://trial.medpath.com/news/dare-bioscience-announces-phase-3-plans-for-sildenafil-globenewswire 2024-12-16T13:01:54+00:00 weekly 0.7 https://trial.medpath.com/news/senti-bio-announces-first-patient-dosed-in-clinical-trial 2024-12-16T13:01:19+00:00 weekly 0.7 https://trial.medpath.com/news/scisparc-advances-11-6m-pharma-portfolio-spin-off-deal-with-miza-ventures-retaining 2024-12-16T12:58:30+00:00 weekly 0.7 https://trial.medpath.com/news/china-approves-merck-s-keytruda-to-treat-patients-with-resectable-stage-ii-iiia-or-iiib-nsclc 2024-12-16T12:57:43+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-vtama-r-tapinarof-cream-1-for-the-treatment-of-atopic-dermatitis-morningstar 2024-12-16T12:47:19+00:00 weekly 0.7 https://trial.medpath.com/news/atsena-therapeutics-announces-dosing-completed-in-part-a-of-globenewswire 2024-12-16T12:31:47+00:00 weekly 0.7 https://trial.medpath.com/news/roche-discontinues-hemophilia-a-gene-therapy-development-shifts-focus-to-enhanced-function-fviii-variant 2024-12-16T12:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/vectory-strengthens-leadership-team-with-appointment-of-jim-scibetta-as-new-ceo 2024-12-16T12:15:07+00:00 weekly 0.7 https://trial.medpath.com/news/foghorn-therapeutics-provides-update-on-fhd-286-clinical-development-program-and 2024-12-16T12:15:07+00:00 weekly 0.7 https://trial.medpath.com/news/2024-key-insights-skin-cancer-dermatology-times 2024-12-16T12:10:32+00:00 weekly 0.7 https://trial.medpath.com/news/ema-recommends-expanding-approval-of-ofev-to-children-and-adolescents 2024-12-16T12:05:48+00:00 weekly 0.7 https://trial.medpath.com/news/fluid-biomed-closes-27-million-usd-series-a-to-fund-expanded-human-clinical-studies 2024-12-16T12:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/caplin-steriles-receives-fda-approval-for-generic-difluprednate-eye-drops-ndtv-profit 2024-12-16T11:58:52+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-oncology-innovations-and-financial-growth-prospects 2024-12-16T11:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-10-year-old-parker-girl-s-disease-is-one-in-a-million-the-colorado-sun 2024-12-16T11:26:30+00:00 weekly 0.7 https://trial.medpath.com/news/mannkind-s-inhaled-insulin-shows-promise-in-pivotal-pediatric-trial-eyes-fda-submission 2024-12-16T11:14:30+00:00 weekly 0.7 https://trial.medpath.com/news/study-supports-tamoxifen-for-dcis-early-breast-cancers 2024-12-16T11:12:42+00:00 weekly 0.7 https://trial.medpath.com/news/edgewise-therapeutics-announces-positive-topline-results-from-the-canyon-phase-2 2024-12-16T11:11:31+00:00 weekly 0.7 https://trial.medpath.com/news/medivir-s-ceo-to-biostock-the-ind-approval-is-a-very-important-milestone-cision-news 2024-12-16T10:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/true-you-weight-loss-announces-two-clinical-trials-exploring-groundbreaking-non 2024-12-16T10:12:07+00:00 weekly 0.7 https://trial.medpath.com/news/sinovac-launches-groundbreaking-phase-3-trial-for-first-global-multivalent-hfmd-vaccine 2024-12-16T10:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/incyclix-bio-reports-outcomes-from-breast-cancer-therapy-trial 2024-12-16T10:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/new-alzheimer-s-treatment-option-now-available-in-lafayette 2024-12-16T10:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/accord-healthcare-is-granted-marketing-authorisation-for-imuldosa-r-ustekinumab 2024-12-16T10:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/exercise-during-cancer-treatment-significantly-improves-survival-rates-in-breast-cancer-patients-roswell-park-study-shows 2024-12-16T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/danish-medicines-agency-seeks-eu-review-of-ozempic-over-risk-of-rare-vision-loss 2024-12-16T09:58:43+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-receives-three-positive-regulatory-updates-on-cancer-products-shares-magazine 2024-12-16T09:38:40+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-pharmaceuticals-ceo-bruce-cozadd-announces-retirement-after-15-year-tenure 2024-12-16T09:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/assertio-therapeutics-receives-buy-rating-following-positive-clinical-trial-results 2024-12-16T09:07:00+00:00 weekly 0.7 https://trial.medpath.com/news/world-economic-forum-report-generative-ai-set-to-transform-clinical-trial-development 2024-12-16T09:03:04+00:00 weekly 0.7 https://trial.medpath.com/news/december-16-2024-study-snapshot-and-updated-ethics-documentation-available-for-i 2024-12-16T09:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/medicare-and-medicaid-see-dramatic-rise-in-rituximab-biosimilar-adoption-achieving-60-market-share-by-2022 2024-12-16T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/shb-raises-target-price-for-egetis-therapeutics-to-sek-16-9-reiterates-buy 2024-12-16T08:19:30+00:00 weekly 0.7 https://trial.medpath.com/news/gh-research-awaits-topline-data-from-gh001-in-treatment-resistant-depression-trial 2024-12-16T08:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-significant-sleep-disruption-among-parents-of-children-with-atopic-dermatitis 2024-12-16T08:07:14+00:00 weekly 0.7 https://trial.medpath.com/news/gerresheimer-fda-grants-tentative-approval-of-sq-innovation-s-lasix-r-onyu-eqs-news 2024-12-16T08:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/inventiva-secures-eur21-4-million-and-completes-the-first-globenewswire 2024-12-16T07:41:24+00:00 weekly 0.7 https://trial.medpath.com/news/exact-therapeutics-announces-fda-clearance-of-ind-for-enact-a-phase-2-trial-in 2024-12-16T07:25:53+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-s-b7-h3-targeted-antibody-drug-conjugate-gsk-227-receives-ema-priority-medicines 2024-12-16T07:15:46+00:00 weekly 0.7 https://trial.medpath.com/news/kraig-biocraft-doubles-spider-silk-gene-complexity-advancing-commercial-production-of-high-performance-biomaterials 2024-12-16T06:45:20+00:00 weekly 0.7 https://trial.medpath.com/news/beigene-acquires-global-rights-to-dualitybio-s-adc-in-milestone-for-nona-biosciences-collaboration-network 2024-12-16T06:26:22+00:00 weekly 0.7 https://trial.medpath.com/news/relief-therapeutics-announces-final-readout-of-pku-golike-clinical-trial-stock-titan 2024-12-16T06:25:19+00:00 weekly 0.7 https://trial.medpath.com/news/cultural-understanding-key-to-addressing-ovarian-cancer-disparities-among-pacific-islanders-study-finds 2024-12-16T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-for-autoimmune-disease-gains-traction-drug-discovery-news 2024-12-16T05:17:26+00:00 weekly 0.7 https://trial.medpath.com/news/wockhardt-rises-10-after-antibiotic-zaynich-undergoing-clinical-trials-facilitates-in-a-liver-transplant 2024-12-16T04:32:51+00:00 weekly 0.7 https://trial.medpath.com/news/wockhardt-shares-add-to-their-220-gain-for-2024-with-another-10-surge-explained 2024-12-16T04:32:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-multiple-breakthrough-therapies-crenessity-for-cah-unloxcyt-for-skin-cancer 2024-12-16T03:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-clinical-trial-landscape-shows-asia-pacific-leading-sclc-research-with-over-1200-studies-since-2019 2024-12-16T03:56:58+00:00 weekly 0.7 https://trial.medpath.com/news/hiro-forges-strategic-partnership-with-cha-university-bundang-medical-center-in-south-korea 2024-12-16T03:02:04+00:00 weekly 0.7 https://trial.medpath.com/news/25-years-of-cgm-innovation-major-advances-mark-2024-as-breakthrough-year-for-glucose-monitoring 2024-12-16T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-powered-ecg-analysis-set-to-transform-pharmaceutical-drug-development-and-clinical-trials 2024-12-16T02:26:15+00:00 weekly 0.7 https://trial.medpath.com/news/european-chmp-recommends-approval-for-four-celltrion-biosimilars-businesskorea 2024-12-16T02:18:27+00:00 weekly 0.7 https://trial.medpath.com/news/pharming-announces-public-cash-offer-to-the-shareholders-of-abliva-ab-stock-titan 2024-12-16T01:19:07+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-shr-1701-to-first-line-capecitabine-and-oxaliplatin-xelox-plus-bevacizumab 2024-12-16T01:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/noninvasive-early-identification-of-durable-clinical-benefit-from-immune-checkpoint-inhibition 2024-12-16T01:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/hs-20093-b7-h3-targeted-antibody-drug-conjugate-receives-ema-priority 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/beckley-psytech-announces-positive-results-for-ele-101-in-depression-trial 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/heartsciences-reports-second-quarter-fiscal-2025-financial-results-and-business-update 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-study-finds-psychedelic-drug-can-help-ease-depression-among-healthcare-workers 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/top-5-most-read-all-aml-articles-in-2024 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eo-3021-demonstrates-effectiveness-in-cldn18-2-expressing-cancer-models 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/trial-investigating-v940-and-pembrolizumab-for-squamous-cell-skin-cancer-treatment 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/success-with-adjuvant-ribociclib-leads-to-fda-approval-in 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/percheron-therapeutics-halts-trading-ahead-of-trial-results 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/invios-to-showcase-oncology-pipeline-progress-at-jp-morgan-week-2025 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/here-are-5-asx-biotechs-expecting-clinical-trial-results-in-the-next-few-months 2024-12-15T23:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/tiny-robots-thinner-than-a-human-hair-could-help-fight-cancer-tumours-reveals-study 2024-12-15T23:51:00+00:00 weekly 0.7 https://trial.medpath.com/news/mixed-signals-from-trials-of-perioperative-neoadjuvant-immunotherapy-for-early-tnbc 2024-12-15T22:46:18+00:00 weekly 0.7 https://trial.medpath.com/news/protagonist-therapeutics-swot-analysis-stock-poised-for-growth-amid-clinical-trials 2024-12-15T21:30:43+00:00 weekly 0.7 https://trial.medpath.com/news/professor-kim-gun-ho-receives-fda-approval-for-ocucool-eye-anesthesia-technology 2024-12-15T21:18:18+00:00 weekly 0.7 https://trial.medpath.com/news/advancing-epilepsy-treatment-with-novel-approaches-and-predictive-technologies-neurologylive 2024-12-15T21:16:25+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-and-neomorph-forge-1-64-billion-molecular-glue-degrader-partnership-for-oncology-and-immunology 2024-12-15T21:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/cwr-expands-clinical-trials-to-tackle-high-disease-burden-in-nigeria-others 2024-12-15T20:49:25+00:00 weekly 0.7 https://trial.medpath.com/news/2nd-phase-transgenic-silkworm-trials-focus-on-virus-resistance-times-of-india 2024-12-15T19:13:57+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-and-2seventy-bio-s-car-t-ide-cel-effects-responses-in-cns-involved 2024-12-15T17:19:11+00:00 weekly 0.7 https://trial.medpath.com/news/lipigon-pharmaceuticals-appoints-new-ceo-marketscreener 2024-12-15T17:01:42+00:00 weekly 0.7 https://trial.medpath.com/news/intas-pharmaceutical-gets-cdsco-panel-nod-to-study-aflibercept-solution-for-injection-40 2024-12-15T16:36:34+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-belzutifan-for-clear-cell-renal-cell-carcinoma-treatment-targeted-oncology 2024-12-15T16:22:28+00:00 weekly 0.7 https://trial.medpath.com/news/stockwatch-q32-shares-crater-85-as-investors-analysts-sour-on-trial-results 2024-12-15T16:07:17+00:00 weekly 0.7 https://trial.medpath.com/news/outpatient-lymphodepletion-prior-to-brexu-cel-is-safe-effective-in-b-all-mcl 2024-12-15T15:55:11+00:00 weekly 0.7 https://trial.medpath.com/news/commentary-kudos-criticism-mark-california-stem-cell-agency-as-it-turns-20-stocktonia 2024-12-15T15:51:14+00:00 weekly 0.7 https://trial.medpath.com/news/promising-combination-therapy-could-improve-liver-cancer-outcomes-news-medical 2024-12-15T14:49:20+00:00 weekly 0.7 https://trial.medpath.com/news/is-pfizer-a-millionaire-maker-yahoo-finance 2024-12-15T14:45:53+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-linked-to-lower-inflammatory-markers-in-women-with-breast-cancer-healio 2024-12-15T14:39:41+00:00 weekly 0.7 https://trial.medpath.com/news/francoise-bernaudin-md-on-allosct-superiority-over-soc-for-sickle-cell-anemia 2024-12-15T14:23:57+00:00 weekly 0.7 https://trial.medpath.com/news/mind-medicine-s-swot-analysis-stock-poised-for-growth-in-anxiety-treatment-investing-com 2024-12-15T14:12:35+00:00 weekly 0.7 https://trial.medpath.com/news/investigational-hepatitis-d-therapy-well-tolerated-safe-for-chronic-disease-at-week-48 2024-12-15T13:26:38+00:00 weekly 0.7 https://trial.medpath.com/news/gan-lee-pharmaceutical-rose-0-68-this-week-and-the-biological-products-sector-fell-1-58 2024-12-15T12:35:48+00:00 weekly 0.7 https://trial.medpath.com/news/2-weight-loss-stocks-that-are-screaming-buys-in-december 2024-12-15T12:17:53+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-s-melanoma-treatment-nears-key-milestones 2024-12-15T11:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/artiva-biotherapeutics-s-swot-analysis-nk-cell-therapy-stock-poised-for-autoimmune-breakthrough 2024-12-15T09:51:26+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-opportunity-for-erectile-dysfunction-treatment 2024-12-15T09:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-gene-therapy-for-haemophilia-a-at-christian-medical-college-vellore 2024-12-15T09:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/yifang-biopharma-on-december-4-it-was-surveyed-by-institutions-including-well-known 2024-12-15T05:53:32+00:00 weekly 0.7 https://trial.medpath.com/news/ponatinib-related-toxicity-management-in-all-cml-improves-over-time-cancer-network 2024-12-15T05:13:27+00:00 weekly 0.7 https://trial.medpath.com/news/fate-therapeutics-advances-in-autoimmune-disease-treatment-with-promising-cell-therapy-programs 2024-12-15T04:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/behind-the-leap-012-trial-of-lenvatinib-pembrolizumab-and-tace-in-hcc 2024-12-15T04:12:13+00:00 weekly 0.7 https://trial.medpath.com/news/inovio-s-swot-analysis-biotech-stock-faces-manufacturing-hurdles-amid-pipeline-progress 2024-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gdf-15-inhibitors-show-promise-against-hard-to-treat-tumors-in-clinical-trial 2024-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/key-highlights-from-the-american-society-of-hematology-meeting-and-regulatory-updates 2024-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/oppenheimer-predicts-significant-growth-for-sagimet-and-y-mabs-therapeutics 2024-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adjuvant-anthracycline-plus-taxane-based-chemotherapy-regimen-improves-survival-in-high 2024-12-14T23:15:18+00:00 weekly 0.7 https://trial.medpath.com/news/psilocybin-industry-will-focus-on-fine-tuning-first-in-the-nation-program-in-2025-opb 2024-12-14T22:48:18+00:00 weekly 0.7 https://trial.medpath.com/news/russia-announces-free-personalized-cancer-vaccine-the-pinnacle-gazette 2024-12-14T21:12:25+00:00 weekly 0.7 https://trial.medpath.com/news/aaron-nagial-md-phd-gives-interview-on-the-impact-of-retinal-gene-therapy-procedure 2024-12-14T20:46:43+00:00 weekly 0.7 https://trial.medpath.com/news/a-low-omega-6-omega-3-rich-diet-and-fish-oil-may-slow-prostate-cancer-growth-ucla-study-finds 2024-12-14T20:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/jennifer-b-green-md-implementation-of-evidence-based-therapies-for-t2d-hcplive 2024-12-14T19:41:46+00:00 weekly 0.7 https://trial.medpath.com/news/sensome-data-supports-clot-sensing-guidewire-massdevice 2024-12-14T18:19:37+00:00 weekly 0.7 https://trial.medpath.com/news/japanese-researchers-test-pioneering-drug-to-regrow-teeth-medical-xpress 2024-12-14T18:09:51+00:00 weekly 0.7 https://trial.medpath.com/news/kura-oncology-s-swot-analysis-ziftomenib-s-promise-drives-stock-outlook-investing-com 2024-12-14T17:23:04+00:00 weekly 0.7 https://trial.medpath.com/news/letter-to-the-fda-commissioner-requesting-an-investigation-of-the-conduct-of-alzheimer-s 2024-12-14T15:39:19+00:00 weekly 0.7 https://trial.medpath.com/news/soxrc-regimen-improves-responses-versus-chemo-alone-in-advanced-gastric-cancers 2024-12-14T15:04:28+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-s-ozempic-reportedly-linked-to-vision-loss-in-new-study-yahoo-finance 2024-12-14T14:42:42+00:00 weekly 0.7 https://trial.medpath.com/news/curateq-biologics-receives-positive-opinion-for-biosimilar-zefylti-indian-pharma-post 2024-12-14T14:07:58+00:00 weekly 0.7 https://trial.medpath.com/news/lower-aldosterone-thresholds-linked-to-increased-hypertension-risk-in-landmark-breakthrough-study 2024-12-14T14:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/what-happened-in-optometry-this-week-december-9 2024-12-14T12:54:07+00:00 weekly 0.7 https://trial.medpath.com/news/phase-i-gynecological-cancer-data-sink-repare-shares-bioworld 2024-12-14T12:33:02+00:00 weekly 0.7 https://trial.medpath.com/news/new-research-highlights-potential-of-diabetes-medications-in-reducing-dementia-risk 2024-12-14T12:30:54+00:00 weekly 0.7 https://trial.medpath.com/news/the-biggest-medical-breakthroughs-of-2024-gizmodo 2024-12-14T12:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-says-andexxa-will-not-convert-to-full-approval-quietly-reveals-complete-response 2024-12-14T11:57:16+00:00 weekly 0.7 https://trial.medpath.com/news/biontech-se-and-its-partner-oncoc4-inc-continue-enrollment-in-phase-3-trial-for-bnt316 2024-12-14T11:39:10+00:00 weekly 0.7 https://trial.medpath.com/news/enrollment-hits-75-for-phase-2b-clinical-trial-of-haduvio-for-ipf-pulmonary-fibrosis-news 2024-12-14T11:28:17+00:00 weekly 0.7 https://trial.medpath.com/news/rising-obesity-in-type-1-diabetes-patients-signals-need-for-new-cardiovascular-treatment-approaches 2024-12-14T10:30:17+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-data-and-ai-help-improve-ild-management-in-her2-breast-cancer 2024-12-14T09:03:30+00:00 weekly 0.7 https://trial.medpath.com/news/new-hpv-self-test-approach-could-enhance-cervical-cancer-screening-news-medical 2024-12-14T08:42:29+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-r-s-weekly-rewind-december-13-2024 2024-12-14T08:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/the-effect-of-acupuncture-intervention-on-chronic-musculoskeletal-pain-jpr-dove-medical-press 2024-12-14T07:17:52+00:00 weekly 0.7 https://trial.medpath.com/news/cg-oncology-positive-phase-3-outcome-could-lead-to-bla-of-cretostimogene 2024-12-14T07:14:46+00:00 weekly 0.7 https://trial.medpath.com/news/ai-powered-mammography-analysis-shows-promise-for-long-term-breast-cancer-prevention 2024-12-14T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/coa-2024-value-based-care-challenges-and-pbm-reform-take-center-stage-in-oncology 2024-12-14T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/miller-school-spinoff-uses-rna-to-tackle-deadly-disease-inventum 2024-12-14T03:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/emerging-research-leveraging-technology-in-phase-i-clinical-trials-massbio 2024-12-14T02:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/study-confirms-semaglutide-link-to-increased-but-low-risk-of-naion-markets-insider 2024-12-14T02:22:08+00:00 weekly 0.7 https://trial.medpath.com/news/edesa-biotech-reports-fiscal-year-2024-results-stock-titan 2024-12-14T01:42:45+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-pipelines-shrink-as-incyte-iteos-cut-candidates-following-disappointing-data 2024-12-14T01:41:33+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-co-brass-face-investor-suit-over-drug-trial-probe-law360 2024-12-14T01:00:43+00:00 weekly 0.7 https://trial.medpath.com/news/new-leash-on-life-cape-coral-shelter-dog-beats-cancer-with-drug-being-tested-for-humans 2024-12-14T00:07:57+00:00 weekly 0.7 https://trial.medpath.com/news/cosibelimab-approved-by-fda-for-metastatic-locally-advanced-cutaneous-squamous-cell 2024-12-14T00:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-suspends-valneva-s-chikungunya-vaccine-license-following-severe-adverse-events-in-elderly-patients 2024-12-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/checkpoint-therapeutics-gets-its-first-fda-approval-morningstar 2024-12-13T23:59:36+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-crinecerfont-for-congenital-adrenal-hyperplasia-hcplive 2024-12-13T23:55:07+00:00 weekly 0.7 https://trial.medpath.com/news/mpox-vaccine-ready-for-clinical-trial-chinadaily-com-cn 2024-12-13T23:25:16+00:00 weekly 0.7 https://trial.medpath.com/news/viridian-therapeutics-to-webcast-veligrotug-phase-3-thrive-2-topline-results-yahoo-finance 2024-12-13T23:13:27+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-service-brightpath-bio-and-cellistic-announces-process-development-and 2024-12-13T23:02:21+00:00 weekly 0.7 https://trial.medpath.com/news/study-promising-drug-for-treating-rare-childhood-cancer-qna 2024-12-13T22:26:22+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-director-ramiro-guerrero-buys-99998-in-stock-investing-com 2024-12-13T22:25:40+00:00 weekly 0.7 https://trial.medpath.com/news/supportive-care-helps-manage-aes-with-teclistamab-in-r-r-multiple-myeloma 2024-12-13T22:19:04+00:00 weekly 0.7 https://trial.medpath.com/news/center-for-biostatistics-in-aids-research-cbar-2024-highlights 2024-12-13T22:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/t-dxd-preserves-qol-neurological-function-in-her2-metastatic-breast-cancer 2024-12-13T21:46:32+00:00 weekly 0.7 https://trial.medpath.com/news/helping-kids-with-cancer-speak-for-the-supportive-care-they-need 2024-12-13T21:17:13+00:00 weekly 0.7 https://trial.medpath.com/news/stimulating-a-nerve-the-long-winding-road-of-vagus-nerve-stimulation-as-a-treatment 2024-12-13T21:14:26+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-sglt-2-inhibitor-may-slow-progression-of-diabetic-retinopathy-in-patients-with 2024-12-13T21:14:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-revokes-emergency-use-authorization-eua-for-bebtelovimab-for-the-treatment-of-covid-19 2024-12-13T21:12:25+00:00 weekly 0.7 https://trial.medpath.com/news/fda-revokes-eua-for-sotrovimab-for-the-treatment-of-covid-19 2024-12-13T21:12:24+00:00 weekly 0.7 https://trial.medpath.com/news/giroctocogene-fitelparvovec-prevents-hem-a-bleeds-new-trial-data 2024-12-13T20:41:13+00:00 weekly 0.7 https://trial.medpath.com/news/gileads-seladelpar-receives-positive-chmp-opinion-for-primary-biliary-cholangitis 2024-12-13T20:31:11+00:00 weekly 0.7 https://trial.medpath.com/news/niraparib-dostarlimab-shows-promise-in-brca-er-her2-breast-cancer 2024-12-13T20:29:57+00:00 weekly 0.7 https://trial.medpath.com/news/say-that-again-cooling-devices-may-prevent-hearing-loss-inventum 2024-12-13T20:18:29+00:00 weekly 0.7 https://trial.medpath.com/news/fda-revokes-eua-for-evusheld-tixagevimab-co-packaged-with-cilgavimab 2024-12-13T20:12:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-oral-antibiotic-to-treat-uncomplicated-utis-drug-discovery-news 2024-12-13T20:05:16+00:00 weekly 0.7 https://trial.medpath.com/news/perioperative-atezolizumab-falls-short-in-tnbc-targeted-oncology 2024-12-13T19:58:39+00:00 weekly 0.7 https://trial.medpath.com/news/hiv-drug-based-in-research-by-sundquist-lab-is-sci-newswise 2024-12-13T19:56:54+00:00 weekly 0.7 https://trial.medpath.com/news/response-rates-were-improved-for-camrelizumab-chemo-vs-chemo-in-tnbc 2024-12-13T19:47:08+00:00 weekly 0.7 https://trial.medpath.com/news/zest-trial-offers-insights-for-using-ctdna-to-predict-breast-cancer-recurrence 2024-12-13T19:19:09+00:00 weekly 0.7 https://trial.medpath.com/news/talquetamab-step-up-dosing-strategies-and-crs-monitoring-targeted-oncology 2024-12-13T19:18:27+00:00 weekly 0.7 https://trial.medpath.com/news/csl-receives-positive-chmp-opinion-for-garadacimab-in-hereditary-angioedema-hae 2024-12-13T18:40:12+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-recommends-approval-of-galderma-s-nemolizumab-for-moderate-to-severe-atopic 2024-12-13T18:18:40+00:00 weekly 0.7 https://trial.medpath.com/news/orca-t-leads-to-retrospective-os-improvement-in-high-risk-hematologic-malignancies 2024-12-13T18:13:33+00:00 weekly 0.7 https://trial.medpath.com/news/high-dose-bi655064-shows-promising-results-in-improving-renal-outcomes-for-people 2024-12-13T17:53:19+00:00 weekly 0.7 https://trial.medpath.com/news/inupadenant-deprioritised-by-iteos-in-favour-of-pipeline-tigit-therapy 2024-12-13T17:44:15+00:00 weekly 0.7 https://trial.medpath.com/news/action-centers-collaborate-with-johnson-johnson-medtech-to-secure-fda-labeling-for 2024-12-13T17:43:21+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-drug-and-medical-trials-revolutionizing-care-for-patients-in-brampton-and-beyond 2024-12-13T17:42:01+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-stock-hits-52-week-low-at-25-16-investing-com 2024-12-13T17:35:51+00:00 weekly 0.7 https://trial.medpath.com/news/tam-anh-general-hospital-joins-global-effort-to-advance-cancer-treatment-with-vista-1-clinical-trial 2024-12-13T17:28:05+00:00 weekly 0.7 https://trial.medpath.com/news/eu-drugs-regulator-backs-mounjaro-s-sleep-apnea-use-without-fresh-approval-for-lilly 2024-12-13T17:24:39+00:00 weekly 0.7 https://trial.medpath.com/news/postoperative-radiation-improves-hrqol-over-endocrine-therapy-in-breast-cancer 2024-12-13T17:18:17+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-shares-drop-38-following-phase-1-trial-results-yahoo-finance 2024-12-13T17:10:08+00:00 weekly 0.7 https://trial.medpath.com/news/sibylle-loibl-on-primary-results-of-the-randomized-phase-iii-padma-study-in-her2 2024-12-13T16:41:36+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-approves-imetelstat-for-transfusion-dependent-anemia-in-lower-risk-mds 2024-12-13T16:36:45+00:00 weekly 0.7 https://trial.medpath.com/news/pharmaceutical-business-updates-from-november-2024 2024-12-13T16:32:52+00:00 weekly 0.7 https://trial.medpath.com/news/dream-hf-trial-sheds-positive-light-on-revascor-for-ischemic-hf-clinical-trials-arena 2024-12-13T16:29:33+00:00 weekly 0.7 https://trial.medpath.com/news/targeting-peptide-antigens-using-a-multiallelic-mhc-i-binding-system-nature-biotechnology 2024-12-13T16:19:47+00:00 weekly 0.7 https://trial.medpath.com/news/intermittent-or-continuous-panitumumab-plus-folfiri-in-first-line-treatment-of-ras-and 2024-12-13T15:41:36+00:00 weekly 0.7 https://trial.medpath.com/news/100-mg-bezuclastinib-improves-symptoms-biomarkers-in-non-advanced-systemic-mastocytosis 2024-12-13T15:21:46+00:00 weekly 0.7 https://trial.medpath.com/news/brain-tumors-hijack-circadian-rhythms-to-accelerate-growth-inside-precision-medicine 2024-12-13T15:15:18+00:00 weekly 0.7 https://trial.medpath.com/news/walgreens-boots-alliance-inc-wba-launches-clinical-trials-patient-advisory-board 2024-12-13T15:12:34+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-splicebio-s-ind-application-to-begin-stargardt-disease-therapy-trial 2024-12-13T15:10:01+00:00 weekly 0.7 https://trial.medpath.com/news/launch-of-largest-ever-study-tracking-chikungunya-burden-in-east-africa 2024-12-13T14:46:20+00:00 weekly 0.7 https://trial.medpath.com/news/stockport-grandad-free-from-blood-cancer-after-being-on-a-clinical-trial-at-the-christie 2024-12-13T14:29:58+00:00 weekly 0.7 https://trial.medpath.com/news/single-cell-rna-sequencing-reveals-transcriptional-changes-in-circulating-immune-cells 2024-12-13T14:16:36+00:00 weekly 0.7 https://trial.medpath.com/news/maic-points-to-improved-os-with-momelotinib-in-ruxolitinib-pretreated-myelofibrosis 2024-12-13T14:06:51+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-omvoh-scores-landmark-chmp-backing-for-crohn-s-disease-first-to-show-stock-titan 2024-12-13T13:51:45+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-biologic-prefilled-syringe-approved-in-eu-european-pharmaceutical-review 2024-12-13T13:36:34+00:00 weekly 0.7 https://trial.medpath.com/news/ub-studies-on-ms-patients-reveal-how-paramagnetic-rim-lesions-evolve-what-they-mean-for 2024-12-13T13:26:15+00:00 weekly 0.7 https://trial.medpath.com/news/multimodal-machine-learning-model-effective-at-predicting-response-to-cdk4-6-inhibitors 2024-12-13T13:19:11+00:00 weekly 0.7 https://trial.medpath.com/news/ben-samelson-jones-md-phd-on-confirming-the-safety-of-pfizer-s-hemophilia-b-gene 2024-12-13T13:07:49+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-advances-corporate-growth-strategy-through-sanofi-partnership-including 2024-12-13T13:04:54+00:00 weekly 0.7 https://trial.medpath.com/news/dcgi-pushes-fast-track-approval-for-rare-disease-drugs-prioritizes-patient-access 2024-12-13T12:58:56+00:00 weekly 0.7 https://trial.medpath.com/news/newron-and-ea-pharma-a-subsidiary-of-eisai-co-ltd-announce-license-agreement-for 2024-12-13T12:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/sec-form-10-q-filed-by-galera-therapeutics-inc-quantisnow 2024-12-13T12:31:16+00:00 weekly 0.7 https://trial.medpath.com/news/geron-corp-gern-receives-positive-chmp-opinion-for-rytelo-in-t-gurufocus 2024-12-13T12:13:47+00:00 weekly 0.7 https://trial.medpath.com/news/the-board-of-directors-decision-on-a-new-execution-strategy-and-prioritisation-of-clinical 2024-12-13T11:27:18+00:00 weekly 0.7 https://trial.medpath.com/news/multispecific-antibodies-market-set-to-exceed-40-billion-as-next-generation-cancer-therapies-advance 2024-12-13T11:24:39+00:00 weekly 0.7 https://trial.medpath.com/news/cost-barriers-lead-to-medication-non-adherence-in-17-8-of-us-asthma-patients-study-reveals 2024-12-13T11:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-agreement-with-fda-on-factors-for-accelerated-approval-process 2024-12-13T10:30:07+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-has-much-riding-on-drug-approval-and-major-strategic-shift-stat-news 2024-12-13T09:34:07+00:00 weekly 0.7 https://trial.medpath.com/news/tyra-300-shows-promise-in-urothelial-cancer-treatment-with-projected-63m-revenue-by-2036 2024-12-13T09:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/adalimumab-biosimilars-drive-45-drop-in-net-spending-despite-limited-market-share 2024-12-13T08:53:36+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-randomized-trial-complementary-analysis-of-immune-persistence-3-6-years-after-priming 2024-12-13T08:34:07+00:00 weekly 0.7 https://trial.medpath.com/news/less-frequent-elfabrio-ert-regimen-for-fabry-up-for-eu-approval 2024-12-13T07:38:49+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-s-tolebrutinib-gets-fda-breakthrough-therapy-designation-for-nrspms 2024-12-13T07:29:15+00:00 weekly 0.7 https://trial.medpath.com/news/rezolute-s-clinical-progress-and-market-potential-highlighted-in-swot-analysis 2024-12-13T06:11:00+00:00 weekly 0.7 https://trial.medpath.com/news/2024-s-most-impactful-gene-therapy-developments-from-cost-challenges-to-access-solutions 2024-12-13T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/missouri-healthcare-system-shows-resilience-amid-historic-medicaid-expansion-survey-reveals 2024-12-13T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/accropeutics-inc-announces-u-s-fda-clearance-of-ind-application-for-ripk2-inhibitor-ac-101 2024-12-13T05:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/biomarker-guided-therapies-transform-treatment-landscape-across-multiple-cancers 2024-12-13T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/briacell-2024-sabcs-r-poster-highlights-ability-of-bria-imttm-regimen-to-increase-cancer-fighting-immune-cells-in-metastatic-breast-cancer 2024-12-13T04:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-treatment-strategies-emerge-for-egfr-mutated-nsclc-as-amivantamab-shows-promise 2024-12-13T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-faces-lawsuit-from-padlock-therapeutics-investors-over-milestone-payment-dispute 2024-12-13T03:46:00+00:00 weekly 0.7 https://trial.medpath.com/news/alphamab-oncology-presents-the-phase-ii-clinical-data-of-kn046-in-combination-with 2024-12-13T03:25:34+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-acquires-nimble-therapeutics-for-200m-expanding-oral-immunology-pipeline 2024-12-13T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/solventum-pioneers-novel-tooth-based-randomization-approach-in-dental-clinical-trials-using-zelta-platform 2024-12-13T02:46:53+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-lack-of-clinical-evidence-behind-popular-dietary-supplements-health-claims 2024-12-13T02:24:20+00:00 weekly 0.7 https://trial.medpath.com/news/nyxoah-expands-global-reach-genio-neurostimulation-therapy-for-osa-launches-in-middle-east-and-england 2024-12-13T01:49:32+00:00 weekly 0.7 https://trial.medpath.com/news/most-patients-with-intermediate-risk-breast-cancer-may-safely-avoid-chest-wall-irradiation 2024-12-13T01:34:09+00:00 weekly 0.7 https://trial.medpath.com/news/ars-pharmaceuticals-announces-filings-for-approval-of-neffy-r-in-china-japan-and-australia 2024-12-13T01:33:47+00:00 weekly 0.7 https://trial.medpath.com/news/interview-mediwhale-pushes-for-fda-approval-to-bring-ai-retinal-scan-to-us-cardiovascular-kbr 2024-12-13T01:01:59+00:00 weekly 0.7 https://trial.medpath.com/news/fda-revokes-euas-for-four-monoclonal-antibody-products 2024-12-13T00:11:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-and-biomarker-analyses-of-shr-1701-combined-with-famitinib-in-patients-with-nature 2024-12-13T00:07:57+00:00 weekly 0.7 https://trial.medpath.com/news/the-daily-hit-december-12-2024-green-market-report 2024-12-13T00:06:05+00:00 weekly 0.7 https://trial.medpath.com/news/solid-biosciences-positioned-for-next-gen-duchenne-muscular-dystrophy-treatment-success-analyst 2024-12-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/university-of-wollongong-secures-500k-grant-to-advance-resectassisttm-cancer-device-for-pancreatic-tumors 2024-12-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bicycle-therapeutics-announces-data-updates-across-zelenectide-pevedotin-program-and 2024-12-12T23:41:49+00:00 weekly 0.7 https://trial.medpath.com/news/2024-sabcs-results-unveiled-for-the-phase-iii-study-of-disitamab-vedotin-in-treating 2024-12-12T23:40:43+00:00 weekly 0.7 https://trial.medpath.com/news/takeda-spotlights-high-value-late-stage-pipeline-accelerating-the-development-of-biospace 2024-12-12T23:29:40+00:00 weekly 0.7 https://trial.medpath.com/news/keros-shares-collapse-on-unanticipated-setback-for-lung-disease-drug-biopharma-dive 2024-12-12T23:15:58+00:00 weekly 0.7 https://trial.medpath.com/news/scott-tagawa-md-highlights-phase-3-trial-of-177lu-tlx591-in-mcrpc-urology-times 2024-12-12T23:03:35+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-s-novel-mash-treatment-combination-clesacostat-ervogastat-projects-16m-revenue-by-2036 2024-12-12T22:59:33+00:00 weekly 0.7 https://trial.medpath.com/news/improving-access-to-nivolumab-by-lowering-age-restrictions-in-clinical-trial 2024-12-12T22:26:59+00:00 weekly 0.7 https://trial.medpath.com/news/corcept-s-als-drug-trial-disappoints-but-zero-deaths-in-high-dose-group-firstword-pharma 2024-12-12T21:43:07+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-announces-positive-results-of-the-lunresertib-and-camonsertib-stock-titan 2024-12-12T21:27:10+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-at-the-neuro-target-myotonic-dystrophy-mcgill-reporter 2024-12-12T21:18:48+00:00 weekly 0.7 https://trial.medpath.com/news/corcept-s-korlym-shows-breakthrough-results-in-phase-4-diabetes-cushing-s-trial-hits 2024-12-12T21:15:40+00:00 weekly 0.7 https://trial.medpath.com/news/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-globenewswire 2024-12-12T21:11:48+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-pharma-s-transcon-hgh-scores-fda-filing-acceptance-after-superior-stock-titan 2024-12-12T21:08:41+00:00 weekly 0.7 https://trial.medpath.com/news/ongoing-trials-may-elucidate-mosunetuzumab-efficacy-in-follicular-lymphoma 2024-12-12T21:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/innocan-pharma-provides-its-annual-state-of-research-and-development-update-for-2024 2024-12-12T21:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/defloria-s-advances-cannabis-based-autism-drug-through-early-trial-green-market-report 2024-12-12T20:20:23+00:00 weekly 0.7 https://trial.medpath.com/news/pitt-led-study-likely-to-change-standard-of-care-strokes-upmc 2024-12-12T20:19:58+00:00 weekly 0.7 https://trial.medpath.com/news/online-vs-face-to-face-pulmonary-rehabilitation-for-copd-patients-a-randomized-controlled-trial 2024-12-12T20:12:00+00:00 weekly 0.7 https://trial.medpath.com/news/shine-study-developing-an-intervention-for-safe-hospital-insulin-use-for-older-or-frail-adults-plos 2024-12-12T20:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/sean-m-healey-amg-center-announces-updates-to-healey-als-platform-trial-master-protocol 2024-12-12T19:26:26+00:00 weekly 0.7 https://trial.medpath.com/news/new-partnership-between-cytophage-orthopedic-innovation-centre-targets-prosthetic 2024-12-12T18:50:13+00:00 weekly 0.7 https://trial.medpath.com/news/targeted-alpha-therapy-market-clinical-trials-proprietary-technologies-insight-biospace 2024-12-12T18:37:25+00:00 weekly 0.7 https://trial.medpath.com/news/autologous-stem-cell-transplantation-may-not-improve-survival-in-patients-with-mcl 2024-12-12T18:35:56+00:00 weekly 0.7 https://trial.medpath.com/news/private-medicare-plans-required-to-cover-biogen-s-als-drug-says-us-agency 2024-12-12T17:51:00+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-completes-acquisition-of-aliada-therapeutics-pharmaceutical-executive 2024-12-12T17:14:07+00:00 weekly 0.7 https://trial.medpath.com/news/kidney-compass-parasol-findings-and-implications-for-fsgs-hcplive 2024-12-12T17:10:09+00:00 weekly 0.7 https://trial.medpath.com/news/commands-trial-luspatercept-long-term-transfusion-benefit-compared-with-epoetin-alfa 2024-12-12T16:55:00+00:00 weekly 0.7 https://trial.medpath.com/news/highest-risk-cll-patients-may-benefit-from-car-t-with-btk-inhibitor-clinical-trials-arena 2024-12-12T16:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/a-randomized-phase-iii-clinical-trial-in-colon-cancer-company-announcement-markets-data 2024-12-12T16:13:17+00:00 weekly 0.7 https://trial.medpath.com/news/sobi-announces-fda-acceptance-of-new-drug-application-for-avatrombopag-doptelet 2024-12-12T15:57:39+00:00 weekly 0.7 https://trial.medpath.com/news/seaport-therapeutics-sees-success-with-allopregnanolone-prodrug-clinical-trials-arena 2024-12-12T15:43:11+00:00 weekly 0.7 https://trial.medpath.com/news/light-therapy-trial-shows-feasibility-of-home-studies-in-parkinson-s 2024-12-12T15:17:32+00:00 weekly 0.7 https://trial.medpath.com/news/december-12-2024-another-year-of-innovations-and-insights-from-the-nih-pragmatic-trials 2024-12-12T15:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/pdc-line-pharma-presents-primary-clinical-results-from-phase-i-ii-trial-on-pdc-lung01 2024-12-12T14:58:56+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-patina-study-shows-hope-for-hr-her2-cancer-mirage-news 2024-12-12T14:58:46+00:00 weekly 0.7 https://trial.medpath.com/news/egetis-receives-positive-chmp-opinion-for-emcitate-r-tiratricol-for-the-treatment-of-mct8-deficiency 2024-12-12T14:44:58+00:00 weekly 0.7 https://trial.medpath.com/news/dr-jitendra-announces-successful-gene-therapy-trial-for-haemophilia-blood-disorder 2024-12-12T14:41:40+00:00 weekly 0.7 https://trial.medpath.com/news/kiromic-biopharma-reports-32-decrease-in-tumor-volume-eight-months-post-treatment 2024-12-12T14:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/cel-sci-s-cancer-drug-multikine-secures-fda-approval-for-pivotal-study-after-73 2024-12-12T14:34:08+00:00 weekly 0.7 https://trial.medpath.com/news/europe-allows-novo-to-include-reduction-of-kidney-disease-in-ozempic-label 2024-12-12T14:33:00+00:00 weekly 0.7 https://trial.medpath.com/news/inupadenant-shows-promise-in-nsclc-phase-2-trial-results-investing-com 2024-12-12T14:31:36+00:00 weekly 0.7 https://trial.medpath.com/news/alx-oncology-to-host-virtual-event-on-new-clinical-data-from-breast-cancer-study 2024-12-12T14:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-expands-indication-for-impella-heart-pumps-to-treat-pediatric-patients-pr-newswire 2024-12-12T14:19:59+00:00 weekly 0.7 https://trial.medpath.com/news/uae-based-biotech-biosapien-secures-5-5-million-pre-series-a-wamda 2024-12-12T14:19:25+00:00 weekly 0.7 https://trial.medpath.com/news/aptevo-s-aml-drug-trial-hits-100-remission-rate-complete-cancer-cell-elimination-in 2024-12-12T14:16:13+00:00 weekly 0.7 https://trial.medpath.com/news/curegene-received-clinical-trial-approval-in-china-for-cg-0255-for-injection 2024-12-12T14:14:54+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-quality-of-life-maintained-with-active-monitoring-for-dcis 2024-12-12T14:10:31+00:00 weekly 0.7 https://trial.medpath.com/news/momelotinib-shows-real-world-improvements-in-anemia-symptoms-and-spleen 2024-12-12T14:06:12+00:00 weekly 0.7 https://trial.medpath.com/news/iteos-therapeutics-presents-interim-a2a-005-clinical-trial-data-translational-and 2024-12-12T14:04:26+00:00 weekly 0.7 https://trial.medpath.com/news/alzamend-neuro-reports-second-quarter-2025-financial-results-and-provides-update-on 2024-12-12T13:52:44+00:00 weekly 0.7 https://trial.medpath.com/news/sk-bioscience-receives-approval-for-global-clinical-trials-of-mrna-japanese-encephalitis 2024-12-12T13:45:30+00:00 weekly 0.7 https://trial.medpath.com/news/knight-therapeutics-announces-regulatory-approval-of-tavalisse-r-in-mexico 2024-12-12T13:09:48+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-s-r-d-approach-scores-dual-wins-against-alexion-s-ultomiris-and-in-lymphoma 2024-12-12T12:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/keros-therapeutics-halts-dosing-in-phase-2-trial-of-cibotercept-combination-in-pah 2024-12-12T12:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/avextra-supports-first-fully-eu-funded-psilocybin-therapy-globenewswire 2024-12-12T12:11:09+00:00 weekly 0.7 https://trial.medpath.com/news/ryvu-therapeutics-provides-an-update-on-rvu120-phase-ii-program-pr-newswire 2024-12-12T11:22:05+00:00 weekly 0.7 https://trial.medpath.com/news/ditch-that-itch-early-findings-offer-hope-for-skin-issues-like-rosacea 2024-12-12T11:12:03+00:00 weekly 0.7 https://trial.medpath.com/news/blue-lake-biotechnology-reports-additional-promising-clinical-data-from-ongoing-pediatric 2024-12-12T11:10:23+00:00 weekly 0.7 https://trial.medpath.com/news/revbio-receives-both-fda-approval-to-expand-its-clinical-trial-and-cms-reimbursement 2024-12-12T10:27:45+00:00 weekly 0.7 https://trial.medpath.com/news/hvivo-unveils-key-covid-19-biomarker-insights-from-human-challenge-study-vox-markets 2024-12-12T10:06:02+00:00 weekly 0.7 https://trial.medpath.com/news/medicare-drug-price-negotiations-show-limited-impact-on-innovation-study-reveals 2024-12-12T09:12:23+00:00 weekly 0.7 https://trial.medpath.com/news/rna-specialist-proqr-therapeutics-nv-bags-us-8-1m-funding-european-biotechnology 2024-12-12T08:59:46+00:00 weekly 0.7 https://trial.medpath.com/news/caris-life-sciences-publishes-large-scale-study-demonstrating-the-critical-role-of-next 2024-12-12T08:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/corcept-announces-results-from-phase-2-study-of-dazucorilant-in-patients-with-biospace 2024-12-12T06:49:07+00:00 weekly 0.7 https://trial.medpath.com/news/research-scientists-ask-gov-t-to-approve-new-drugs-with-highest-efficacy-of-preventing-hiv 2024-12-12T06:26:46+00:00 weekly 0.7 https://trial.medpath.com/news/tils-assessment-emerges-as-powerful-tool-for-personalizing-breast-cancer-treatment-decisions 2024-12-12T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/douglas-tsao-maintains-buy-rating-on-xenon-pharmaceuticals-azetukalner 2024-12-12T05:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/absci-advances-in-ai-driven-drug-development-and-pipeline-updates-at-2024-r-d-day 2024-12-12T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/leicester-patients-to-get-early-access-to-potentially-life-changing-treatments-as-new-funding 2024-12-12T04:31:08+00:00 weekly 0.7 https://trial.medpath.com/news/hutchmed-announces-breakthrough-therapy-designation-in-china-for-orpathys-r-and 2024-12-12T04:15:37+00:00 weekly 0.7 https://trial.medpath.com/news/the-vegf-x-pd-l-1-pipeline-is-growing-and-tnbc-may-benefit-biocentury 2024-12-12T03:26:46+00:00 weekly 0.7 https://trial.medpath.com/news/prospect-lung-trial-aims-to-improve-treatment-for-patients-with-resectable-non-small-cell 2024-12-12T03:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/doubts-over-landmark-heart-drug-trial-ticagrelor-plato-study-the-bmj 2024-12-12T01:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/nec-announces-interim-results-from-phase-1-clinical-trial-of-necvax-neo1 2024-12-12T01:05:03+00:00 weekly 0.7 https://trial.medpath.com/news/givlaari-effective-in-aip-patients-often-excluded-from-clinical-trials-porphyria-news 2024-12-12T00:00:03+00:00 weekly 0.7 https://trial.medpath.com/news/ror1-a-promising-target-for-cancer-therapy 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/isatuximab-irfc-sarclisa-approved-for-multiple-myeloma-treatment 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ladrx-plans-nda-submission-for-aldoxorubicin-under-505-b-2-pathway 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-drugs-may-also-treat-addiction-alzheimers-and-heart-disease 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/boundless-bio-announces-pipeline-and-leadership-updates 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-initiates-phase-i-study-with-sos1-inhibitor-for-advanced-kras-mutated-tumours 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/how-revolutionary-ucsf-study-hopes-to-help-people-with-traumatic-brain-injuries 2024-12-11T23:58:21+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-sees-bright-future-for-registry-based-randomized-clinical-trials 2024-12-11T23:34:11+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-ceo-bourla-prevails-against-starboard-s-1b-activist-challenge 2024-12-11T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-haven-biopharma-firm-veradermics-raises-75m-in-series-b-financing-round 2024-12-11T22:33:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-neffy-new-nasal-spray-to-treat-severe-allergic-reactions-el-estoque 2024-12-11T22:28:51+00:00 weekly 0.7 https://trial.medpath.com/news/with-new-data-lilly-sets-pace-for-next-wave-of-breast-cancer-drugs-biopharma-dive 2024-12-11T22:27:04+00:00 weekly 0.7 https://trial.medpath.com/news/study-uses-ai-to-cast-light-on-harmful-drug-drug-interactions-vumc-news 2024-12-11T21:52:41+00:00 weekly 0.7 https://trial.medpath.com/news/patritumab-deruxtecan-with-without-letrozole-shows-comparable-efficacy-in-hr-her2 2024-12-11T21:33:19+00:00 weekly 0.7 https://trial.medpath.com/news/ash-2024-discussions-shine-spotlight-on-advances-in-haemophilia-treatments 2024-12-11T21:22:29+00:00 weekly 0.7 https://trial.medpath.com/news/anaptysbio-pulls-out-of-eczema-drug-race-after-phase-ii-flop-firstword-pharma 2024-12-11T21:13:20+00:00 weekly 0.7 https://trial.medpath.com/news/fempulse-receives-fda-ide-approval-for-the-pivotal-clinical-trial-of-its-wearable-morningstar 2024-12-11T20:44:40+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-s-rsv-vaccines-run-into-safety-roadblock-biospace 2024-12-11T19:54:04+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-jabs-like-ozempic-may-reduce-effectiveness-of-breast-cancer-treatments-study-finds 2024-12-11T19:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-shr-a1811-demonstrates-efficacy-safety-in-her2-breast-cancer 2024-12-11T19:38:18+00:00 weekly 0.7 https://trial.medpath.com/news/anne-sophie-michallet-md-phd-on-mrd-guided-vs-standard-combination-therapy-for 2024-12-11T19:21:40+00:00 weekly 0.7 https://trial.medpath.com/news/t-dxd-improves-pfs-irrespective-of-time-to-progression-type-of-endocrine-resistance-onclive 2024-12-11T19:13:48+00:00 weekly 0.7 https://trial.medpath.com/news/sound-pharma-gets-positive-results-from-meniere-s-disease-drug-clinical-trial 2024-12-11T19:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-ceo-to-present-at-oppenheimer-movers-in-rare-disease-summit-quantisnow 2024-12-11T18:23:27+00:00 weekly 0.7 https://trial.medpath.com/news/cardiff-oncology-reports-promising-phase-2-trial-results-yahoo-finance 2024-12-11T18:20:20+00:00 weekly 0.7 https://trial.medpath.com/news/covid-19-vaccine-efficacy-reduced-with-immunosuppressive-antiviral-hbv-drug-use 2024-12-11T18:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/cardiff-oncology-announces-positive-colorectal-data-and-40m-stock-oversubscription 2024-12-11T17:51:20+00:00 weekly 0.7 https://trial.medpath.com/news/ready-set-food-and-obviohealth-complete-recruitment-for-infant-food-allergy-study 2024-12-11T17:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/anaptys-announces-phase-2b-trial-of-anb032-a-btla-agonist-did-not-meet-primary-or 2024-12-11T17:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/enrollment-open-for-trial-testing-nkx019-cell-therapy-in-aav-anca-vasculitis-news 2024-12-11T17:16:38+00:00 weekly 0.7 https://trial.medpath.com/news/caredx-partners-with-tc-biopharm-to-support-achieve-clinical-trial-using-allocell-biospace 2024-12-11T17:11:49+00:00 weekly 0.7 https://trial.medpath.com/news/can-2409-improves-dfs-in-intermediate-high-risk-localized-prostate-cancer-onclive 2024-12-11T17:02:53+00:00 weekly 0.7 https://trial.medpath.com/news/brain-sensing-car-t-cells-enhance-brain-tumor-therapy-inside-precision-medicine 2024-12-11T17:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/gc-biopharma-s-hunterase-icv-approved-in-russia-for-severe-hunter-syndrome 2024-12-11T17:01:11+00:00 weekly 0.7 https://trial.medpath.com/news/memed-s-sepsis-test-receives-fda-breakthrough-device-status 2024-12-11T16:51:41+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-testing-sublingual-cladribine-planned-for-next-year 2024-12-11T16:46:38+00:00 weekly 0.7 https://trial.medpath.com/news/astria-therapeutics-announces-positive-final-results-from-target-enrollment-in-the-alpha 2024-12-11T16:45:38+00:00 weekly 0.7 https://trial.medpath.com/news/q32-bio-battered-by-study-failure-of-immune-drug-biopharma-dive 2024-12-11T16:16:52+00:00 weekly 0.7 https://trial.medpath.com/news/benevolentai-restructures-lilly-preps-15b-buyback-program-biopharma-dive 2024-12-11T16:16:51+00:00 weekly 0.7 https://trial.medpath.com/news/gnt-pharma-reports-significant-improvements-in-stroke-patients-treated-with-its-pr-newswire 2024-12-11T16:16:41+00:00 weekly 0.7 https://trial.medpath.com/news/visible-trial-advances-diversity-in-psoriasis-research 2024-12-11T16:05:40+00:00 weekly 0.7 https://trial.medpath.com/news/candel-therapeutics-stock-up-172-after-phase-iii-prostate-cancer-success 2024-12-11T15:50:08+00:00 weekly 0.7 https://trial.medpath.com/news/indian-scientists-develop-novel-gene-therapy-treatment-for-haemophilia 2024-12-11T15:41:00+00:00 weekly 0.7 https://trial.medpath.com/news/updated-hep-b-vaccine-more-effective-for-people-with-hiv-newsroom 2024-12-11T15:37:31+00:00 weekly 0.7 https://trial.medpath.com/news/lynparza-r-olaparib-demonstrated-clinically-meaningful-prolonged-survival-benefit-in 2024-12-11T15:36:42+00:00 weekly 0.7 https://trial.medpath.com/news/rapidpulse-receives-fda-approval-to-begin-ide-study-in-ischemic-stroke-using-innovative 2024-12-11T15:36:04+00:00 weekly 0.7 https://trial.medpath.com/news/lynparza-r-olaparib-demonstrated-clinically-meaningful-prolonged-survival-benefit-in 2024-12-11T15:27:39+00:00 weekly 0.7 https://trial.medpath.com/news/gland-pharma-gets-us-fda-approval-for-vitamin-k-deficiency-injectable-cnbc-tv18 2024-12-11T15:24:06+00:00 weekly 0.7 https://trial.medpath.com/news/neurosense-receives-positive-fda-feedback-on-phase-3-study-design-for-primec 2024-12-11T14:59:06+00:00 weekly 0.7 https://trial.medpath.com/news/ash-2024-inmind-study-results-position-monjuvi-as-a-promising-therapy-for-r-r-follicular-lymphoma 2024-12-11T14:56:25+00:00 weekly 0.7 https://trial.medpath.com/news/ash24-leukemia-drug-sequencing-sickle-cell-questions-and-a-new-kind-of-car-t 2024-12-11T14:44:10+00:00 weekly 0.7 https://trial.medpath.com/news/nature-biotechnology-generative-chemistry-enables-insilico-to-develop-gut-restricted 2024-12-11T14:30:46+00:00 weekly 0.7 https://trial.medpath.com/news/provectus-biopharmaceuticals-launches-visirose-provectus-s-globenewswire 2024-12-11T14:11:28+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-could-treat-alzheimer-s-disease-drug-discovery-news 2024-12-11T14:08:27+00:00 weekly 0.7 https://trial.medpath.com/news/transposon-presents-results-from-successful-phase-2-als-ftd-clinical-trial-aftd 2024-12-11T14:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/60-degrees-pharma-expands-promising-babesiosis-treatment-trial-to-brigham-women-s-hospital 2024-12-11T13:59:37+00:00 weekly 0.7 https://trial.medpath.com/news/aprea-therapeutics-advances-novel-cancer-drug-trial-with-breakthrough-dosing-strategy 2024-12-11T13:37:58+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-s-annamycin-shows-breakthrough-results-against-drug-resistant-leukemia-in-key-study 2024-12-11T13:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/satellos-announces-first-participant-with-duchenne-muscular-dystrophy-dosed-in-the-biospace 2024-12-11T12:50:04+00:00 weekly 0.7 https://trial.medpath.com/news/adams-clinical-announces-expansion-into-inpatient-psychiatry-and-schizophrenia-morningstar 2024-12-11T12:48:07+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-legend-shrug-off-carvykti-s-challengers-with-new-phase-iii-data-biospace 2024-12-11T12:46:56+00:00 weekly 0.7 https://trial.medpath.com/news/reunion-neuroscience-presented-re104-phase-1-data-at-the-globenewswire 2024-12-11T12:44:27+00:00 weekly 0.7 https://trial.medpath.com/news/review-confirms-clinical-safety-of-sandoz-denosumab-biosimilar-vs-originator 2024-12-11T12:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/pharming-announces-positive-topline-data-in-pediatric-clinical-trial-of-leniolisib 2024-12-11T12:02:52+00:00 weekly 0.7 https://trial.medpath.com/news/daiichi-sankyo-doses-first-subject-in-phase-iii-aml-therapy-trial 2024-12-11T11:57:47+00:00 weekly 0.7 https://trial.medpath.com/news/seastar-medical-projects-multibillion-dollar-market-globenewswire 2024-12-11T11:56:35+00:00 weekly 0.7 https://trial.medpath.com/news/fcrn-inhibitor-market-size-target-population-competitive-globenewswire 2024-12-11T11:27:02+00:00 weekly 0.7 https://trial.medpath.com/news/immunotech-biopharm-ltd-announces-car-t-19-injection-receives-breakthrough-therapy 2024-12-11T11:20:33+00:00 weekly 0.7 https://trial.medpath.com/news/women-with-cancer-can-safely-use-rogaine-to-curb-hair-loss 2024-12-11T11:12:50+00:00 weekly 0.7 https://trial.medpath.com/news/removing-storing-patient-s-blood-before-liver-surgery-helps-avoid-transfusions 2024-12-11T11:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-to-host-webcast-to-report-data-from-the-lunresertib-and-camonsertib 2024-12-11T11:04:41+00:00 weekly 0.7 https://trial.medpath.com/news/hunt-for-next-obesity-breakthrough-sends-biotech-stock-soaring-health-tech-world 2024-12-11T11:01:32+00:00 weekly 0.7 https://trial.medpath.com/news/microbot-medical-r-announces-fda-submission-for-the-commercialization-of-the-liberty 2024-12-11T10:53:37+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-two-combination-vaccine-candidates-for-prevention-of-influenza-and-covid 2024-12-11T10:45:36+00:00 weekly 0.7 https://trial.medpath.com/news/ionctura-reaches-new-clinical-milestones-in-uveal-melanoma-pr-newswire 2024-12-11T10:43:44+00:00 weekly 0.7 https://trial.medpath.com/news/will-eli-lilly-s-blockbuster-obesity-drug-be-available-in-india-by-2025-business-today 2024-12-11T10:41:54+00:00 weekly 0.7 https://trial.medpath.com/news/insilico-medicine-advances-with-generative-ai-in-drug-discovery 2024-12-11T09:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/cyrus-biotechnology-advances-cyr212-for-chronic-autoimmune-diseases-with-improved-igg-depletion-profile 2024-12-11T09:07:32+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-liga-chem-bio-s-ind-for-novel-adc-cancer-therapy-komedidaskeom 2024-12-11T09:07:09+00:00 weekly 0.7 https://trial.medpath.com/news/tasca-therapeutics-launches-with-52-million-series-a-financing-to-develop-small-biospace 2024-12-11T08:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/noema-pharma-ag-extends-series-b-financing-european-biotechnology-magazine 2024-12-11T08:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/osf-partners-with-the-kevin-brown-strong-foundation-to-fight-glioblastoma-with-clinical-trials 2024-12-11T08:30:09+00:00 weekly 0.7 https://trial.medpath.com/news/strategic-dose-rounding-in-biologics-balancing-cost-savings-with-patient-safety 2024-12-11T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-cost-barriers-us-healthcare-faces-20-4-billion-annual-spending-challenge 2024-12-11T07:13:18+00:00 weekly 0.7 https://trial.medpath.com/news/most-scd-patients-given-lyfgenia-in-trials-stay-free-of-voes-new-data 2024-12-11T06:12:31+00:00 weekly 0.7 https://trial.medpath.com/news/news-researchers-launch-clinical-trial-testing-stellenbosch-university 2024-12-11T06:09:19+00:00 weekly 0.7 https://trial.medpath.com/news/survey-reveals-top-challenges-for-biotechs-in-early-phase-clinical-trials 2024-12-11T05:23:58+00:00 weekly 0.7 https://trial.medpath.com/news/gbm-organoids-models-patient-response-to-car-t-cell-therapy-in-real-time 2024-12-11T05:01:40+00:00 weekly 0.7 https://trial.medpath.com/news/new-biomarker-testing-protocol-could-shorten-antibiotic-treatment-for-sepsis-news-medical 2024-12-11T04:15:27+00:00 weekly 0.7 https://trial.medpath.com/news/dr-wang-on-ziftomenib-plus-intensive-induction-in-newly-diagnosed-mutated-aml 2024-12-11T03:48:24+00:00 weekly 0.7 https://trial.medpath.com/news/novel-drug-fails-for-two-rare-seizure-disorders-medpage-today 2024-12-11T03:26:59+00:00 weekly 0.7 https://trial.medpath.com/news/pilatus-biosciences-inc-secures-fda-orphan-drug-designation-for-plt012-pr-newswire 2024-12-11T03:13:38+00:00 weekly 0.7 https://trial.medpath.com/news/a-continued-evolution-psychiatric-times 2024-12-11T03:01:26+00:00 weekly 0.7 https://trial.medpath.com/news/november-s-fda-approvals-include-autolus-cd19-car-t-biocentury 2024-12-11T02:17:17+00:00 weekly 0.7 https://trial.medpath.com/news/glofitamab-plus-polatuzumab-shows-durable-results-in-r-r-lbcl-targeted-oncology 2024-12-11T01:32:52+00:00 weekly 0.7 https://trial.medpath.com/news/bringing-it-all-back-home-reshaping-ophthalmology-s-clinic-with-home-oct-hcplive 2024-12-11T01:06:26+00:00 weekly 0.7 https://trial.medpath.com/news/kira-pharmaceuticals-presents-updated-data-of-phase-2-study-of-kp104-in-paroxysmal 2024-12-11T01:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/tyra-biosciences-stock-target-adjusted-following-clinical-data-review 2024-12-11T00:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/visirose-unveils-breakthrough-therapy-for-eye-infections-mirage-news 2024-12-11T00:44:58+00:00 weekly 0.7 https://trial.medpath.com/news/psyence-biomed-executes-binding-agreements-with-optimi-health-corp-stock-titan 2024-12-11T00:39:10+00:00 weekly 0.7 https://trial.medpath.com/news/iv-form-of-nac-receives-fda-snda-to-prevent-lessen-liver-injury-after-ingesting-toxic 2024-12-11T00:23:58+00:00 weekly 0.7 https://trial.medpath.com/news/alternating-modified-capox-capiri-plus-bevacizumab-in-untreated-unresectable-metastatic 2024-12-11T00:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/prophylactic-tocilizumab-may-enhance-access-to-bispecific-therapies-for-multiple-myeloma 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-price-target-lowered-to-13-from-15-at-wells-fargo-tipranks-com 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/prospective-clinical-utility-study-of-lucid-diagnostics-esoguard-r-esophageal-dna-test-accepted-for-peer-reviewed-publication 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/teclistamab-shows-promising-results-in-chinese-patients-with-relapsed-refractory-multiple-myeloma 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/point72-asset-management-l-p-has-1-23-million-position-in-acelyrin-inc-nasdaq-slrn 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-selected-for-new-covid-19-clinical-trial-in-asia-pacific 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/belhaven-biopharma-to-present-nasdepi-r-data-at-ddl-2024 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-future-of-factor-xi-inhibitors-in-atrial-fibrillation-treatment 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-clinical-trial-of-etns-for-pediatric-adhd-to-commence-in-denmark 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/accent-therapeutics-doses-first-patient-in-phase-1-2-trial-of-atx-559-and-announces-cso-transition 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/protaryx-medical-completes-first-in-human-trial-of-transseptal-puncture-device 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-announces-first-patient-in-for-phase-1-clinical-trial-evaluating-ide161-in-pr-newswire 2024-12-10T23:01:04+00:00 weekly 0.7 https://trial.medpath.com/news/mirum-pharmaceuticals-advances-in-liver-disease-treatments 2024-12-10T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/therapy-for-genetic-epilepsy-in-children-showing-promise-vumc-news 2024-12-10T22:52:50+00:00 weekly 0.7 https://trial.medpath.com/news/positive-new-data-and-strong-recruitment-in-pancreatic-cancer-trial-biomelbourne-network 2024-12-10T22:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/ignite-biomedical-achieves-key-milestone-in-precision-medicine-with-successful-analytical 2024-12-10T22:09:27+00:00 weekly 0.7 https://trial.medpath.com/news/cellectar-biosciences-provides-strategic-update-on-clinical-development-pipeline 2024-12-10T22:03:59+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-announces-topline-results-from-phase-2b-3-globenewswire 2024-12-10T21:46:29+00:00 weekly 0.7 https://trial.medpath.com/news/therapeutic-clinical-trial-eligibility-and-enrollment-among-women-with-breast-cancer 2024-12-10T21:12:13+00:00 weekly 0.7 https://trial.medpath.com/news/moberg-pharma-reports-topline-data-in-the-north-american-phase-3-study-and-will-regain 2024-12-10T20:49:34+00:00 weekly 0.7 https://trial.medpath.com/news/axi-cel-demonstrates-long-term-efficacy-in-relapsed-refractory-follicular-lymphoma-and-marginal-zone-lymphoma 2024-12-10T20:33:10+00:00 weekly 0.7 https://trial.medpath.com/news/md-anderson-and-ammax-bio-announce-agreements-to-advance-development-of-amb-066 2024-12-10T20:18:39+00:00 weekly 0.7 https://trial.medpath.com/news/nih-study-finds-tecovirimat-was-safe-but-did-not-improve-mpox-resolution-or-pain 2024-12-10T20:16:23+00:00 weekly 0.7 https://trial.medpath.com/news/hope-for-parkinson-s-disease-symptoms-is-found-in-late-stage-drug-study-fortune 2024-12-10T20:13:29+00:00 weekly 0.7 https://trial.medpath.com/news/pirtobrutinib-triplet-improves-mrd-outcomes-in-cll-cancer-network 2024-12-10T20:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/astria-therapeutics-announces-fda-clearance-of-ind-application-for-star-0310-a-biospace 2024-12-10T19:41:48+00:00 weekly 0.7 https://trial.medpath.com/news/revolutionary-cancer-drug-could-remove-side-effects-from-radiation-treatments-study-finds 2024-12-10T19:40:38+00:00 weekly 0.7 https://trial.medpath.com/news/lisata-therapeutics-announces-completion-of-enrollment-in-the-cendifox-trial 2024-12-10T19:39:48+00:00 weekly 0.7 https://trial.medpath.com/news/harnessing-ai-for-smarter-health-policy-research-school-of-public-health-brown-university 2024-12-10T19:19:49+00:00 weekly 0.7 https://trial.medpath.com/news/cervomed-announces-topline-data-from-rewind-lb-phase-2b-clinical-trial-in-patients-with 2024-12-10T19:12:07+00:00 weekly 0.7 https://trial.medpath.com/news/ash-2024-regeneron-s-ordspono-faces-challenges-but-positive-results-signal-hope 2024-12-10T19:11:41+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-to-test-obesity-medications-as-treatments-for-alcohol-and-drug-addiction-stat-news 2024-12-10T19:05:14+00:00 weekly 0.7 https://trial.medpath.com/news/alveron-pharma-closes-eur5-million-seed-extension-financing-to-accelerate-breakthrough-ich-therapy 2024-12-10T18:50:41+00:00 weekly 0.7 https://trial.medpath.com/news/geron-announces-new-imerge-analyses-presented-at-ash-suggesting-clinical-activity-of 2024-12-10T18:41:35+00:00 weekly 0.7 https://trial.medpath.com/news/arvinas-pfizer-partner-cancer-drug-trial-shows-63-clinical-benefit-in-breast-cancer-patients 2024-12-10T18:31:47+00:00 weekly 0.7 https://trial.medpath.com/news/btk-degrader-bgb-16673-shows-promise-in-r-r-wm-and-cll-sll-cancer-network 2024-12-10T18:28:23+00:00 weekly 0.7 https://trial.medpath.com/news/new-strategy-for-vivoryon-as-second-failed-alzheimer-s-trial-shows-kidney-promise 2024-12-10T18:15:47+00:00 weekly 0.7 https://trial.medpath.com/news/carvykti-significantly-boosts-survival-mrd-negativity-in-relapsed-multiple-myeloma 2024-12-10T17:26:52+00:00 weekly 0.7 https://trial.medpath.com/news/merus-mrus-fda-approval-and-speculative-future-in-cancer-therapy-yahoo-finance 2024-12-10T17:13:40+00:00 weekly 0.7 https://trial.medpath.com/news/ramose-phase-ii-trial-finds-promising-results-for-osimertinib-and-ramucirumab-in-non-small 2024-12-10T16:14:47+00:00 weekly 0.7 https://trial.medpath.com/news/humanetics-secures-additional-funding-to-advance-development-of-its-drug-to-prevent 2024-12-10T15:55:19+00:00 weekly 0.7 https://trial.medpath.com/news/pafolacianine-shows-no-serious-adverse-effects-in-lung-cancer-surgery 2024-12-10T15:26:04+00:00 weekly 0.7 https://trial.medpath.com/news/uk-clinical-trials-performance-improves-but-remains-in-intensive-care 2024-12-10T15:09:49+00:00 weekly 0.7 https://trial.medpath.com/news/why-is-cancer-focused-chimerix-stock-trading-higher-on-tuesday-yahoo-finance 2024-12-10T14:50:08+00:00 weekly 0.7 https://trial.medpath.com/news/the-start-center-for-cancer-research-expands-its-capabilities-to-support-early-phase 2024-12-10T14:44:29+00:00 weekly 0.7 https://trial.medpath.com/news/genmab-delivers-promising-data-from-cancer-drug-in-two-new-clinical-trials-medwatch 2024-12-10T14:25:38+00:00 weekly 0.7 https://trial.medpath.com/news/uniqure-gets-fda-ok-to-seek-accelerated-approval-stat-news 2024-12-10T14:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/atossa-therapeutics-to-present-pharmacokinetic-and-globenewswire 2024-12-10T14:10:43+00:00 weekly 0.7 https://trial.medpath.com/news/theradaptive-obtains-fda-ide-approval-to-study-osteoadapttm-sp-in-additional-spinal 2024-12-10T14:04:16+00:00 weekly 0.7 https://trial.medpath.com/news/thiogenesis-announces-presentation-on-umdf-webcast-featuring-clinical-trials-in 2024-12-10T14:03:56+00:00 weekly 0.7 https://trial.medpath.com/news/curis-reports-promising-aml-study-results-by-investing-com 2024-12-10T13:46:13+00:00 weekly 0.7 https://trial.medpath.com/news/sirus-therapeutics-announces-positive-signals-from-phase-i-sirna-trial 2024-12-10T13:43:46+00:00 weekly 0.7 https://trial.medpath.com/news/heart-specialists-praise-health-canada-approval-of-weight-loss-drug-wegovy-cp24 2024-12-10T13:41:18+00:00 weekly 0.7 https://trial.medpath.com/news/sellas-life-sciences-triggers-interim-analysis-in-phase-3-regal-trial-of-gps-in-acute 2024-12-10T13:39:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-opens-accelerated-approval-path-for-clene-s-breakthrough-als-treatment-after-78 2024-12-10T13:32:28+00:00 weekly 0.7 https://trial.medpath.com/news/curocell-s-car-t-therapy-picked-as-2nd-drug-for-expediated-approval-and-market-launch 2024-12-10T13:24:10+00:00 weekly 0.7 https://trial.medpath.com/news/global-biosimilars-market-set-to-triple-to-114-billion-by-2031-driven-by-patent-expirations-and-cost-advantages 2024-12-10T13:23:20+00:00 weekly 0.7 https://trial.medpath.com/news/sutro-biopharma-announces-selected-dose-for-luvelta-and-globenewswire 2024-12-10T13:11:34+00:00 weekly 0.7 https://trial.medpath.com/news/renovorx-ceo-to-host-investor-fireside-chat-on-tuesday-december-17th-at-4-30-p-m-et 2024-12-10T13:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/onkure-announces-encouraging-preliminary-safety-and-pharmacokinetic-data-from-pikture-01-trial-of-oki-219 2024-12-10T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/quantum-biopharma-progresses-with-drug-trial-dosing-investing-com 2024-12-10T12:46:43+00:00 weekly 0.7 https://trial.medpath.com/news/lyell-immunopharma-announces-promising-initial-clinical-data-for-impt-314-in-treatment 2024-12-10T12:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/uniqure-announces-alignment-with-fda-on-key-elements-of-accelerated-approval-pathway 2024-12-10T12:13:30+00:00 weekly 0.7 https://trial.medpath.com/news/scilex-forms-major-joint-venture-to-develop-novel-obesity-alzheimer-s-drug-after 2024-12-10T12:06:36+00:00 weekly 0.7 https://trial.medpath.com/news/merakris-therapeutics-announces-open-enrollment-for-phase-ii-clinical-trial-of-financial-post 2024-12-10T11:34:24+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-meds-may-lower-clot-risk-in-people-with-diabetes 2024-12-10T11:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/iaso-bio-s-car-t-therapy-shows-sustained-efficacy-in-multiple-myeloma-patients-with-renal-impairment 2024-12-10T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hvivo-plc-aim-hvo-ps11-5m-rsv-contract-and-notice-of-trading-update-share-talk 2024-12-10T09:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/olverembatinib-shows-promise-as-second-line-therapy-for-non-t315i-mutant-cp-cml 2024-12-10T08:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/ixico-lands-ps500k-phase-ii-huntington-s-contract-aim-ixi-otc-phyof-proactive-investors 2024-12-10T08:12:20+00:00 weekly 0.7 https://trial.medpath.com/news/santhera-receives-positive-recommendation-from-nice-for-agamree-r-vamorolone-as 2024-12-10T06:11:28+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-tavapadon-shows-promise-in-phase-3-parkinson-s-disease-trial 2024-12-10T06:06:25+00:00 weekly 0.7 https://trial.medpath.com/news/new-and-updated-data-for-roche-s-fixed-duration-columvi-and-globenewswire 2024-12-10T06:02:08+00:00 weekly 0.7 https://trial.medpath.com/news/experts-challenge-os-as-gold-standard-endpoint-in-cancer-drug-trials-pfs-gains-clinical-relevance 2024-12-10T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/comprehensive-management-guidelines-released-for-talquetamab-treatment-in-multiple-myeloma-patients 2024-12-10T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eye-disease-focused-kodiak-sciences-is-a-promising-turnaround-story-for-2025-benzinga 2024-12-10T05:36:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approved-vowst-offers-novel-treatment-approach-for-recurrent-c-difficile-infections 2024-12-10T05:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/immune-onc-therapeutics-presents-updated-data-from-phase-1b-study-of-io-202-biospace 2024-12-10T05:02:14+00:00 weekly 0.7 https://trial.medpath.com/news/lyell-presents-positive-initial-clinical-data-from-the-phase-1-2-clinical-trial-of-impt-314-for 2024-12-10T05:02:14+00:00 weekly 0.7 https://trial.medpath.com/news/glenmark-s-blood-cancer-drug-isb-2001-shows-83-response-rate-in-phase-1-multiple-myeloma-trial 2024-12-10T04:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-initiates-phase-iii-trial-for-lung-cancer-markets-insider 2024-12-10T03:49:41+00:00 weekly 0.7 https://trial.medpath.com/news/pediatric-cancer-clinical-trial-research-should-include-social-determinants-of-health 2024-12-10T02:50:02+00:00 weekly 0.7 https://trial.medpath.com/news/ghana-becomes-first-river-blindness-endemic-country-to-approve-moxidectin-biomelbourne-network 2024-12-10T02:39:40+00:00 weekly 0.7 https://trial.medpath.com/news/zealand-pharma-announces-first-participant-enrolled-in-phase-2b-zupreme-1-trial-of-petrelintide-in-people-with-overweight-or-obesity 2024-12-10T02:12:56+00:00 weekly 0.7 https://trial.medpath.com/news/beigene-s-brukinsa-shows-breakthrough-71-risk-reduction-in-5-year-cll-study-at-ash 2024-12-10T01:31:17+00:00 weekly 0.7 https://trial.medpath.com/news/comprehensive-treatment-options-expand-for-non-familial-hypercholesterolemia-management 2024-12-10T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-white-paper-highlights-critical-success-factors-for-modern-pharmaceutical-product-launches 2024-12-10T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kites-yescarta-only-car-t-cell-therapy-to-show-durable-response-and-long-gilead-sciences 2024-12-10T00:34:16+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-gene-therapy-offers-new-hope-to-child-with-muscular-dystrophy-the-tennessean 2024-12-10T00:18:40+00:00 weekly 0.7 https://trial.medpath.com/news/positive-phase-3-trial-results-for-rilzabrutinib-support-buy-rating 2024-12-10T00:07:00+00:00 weekly 0.7 https://trial.medpath.com/news/tempus-announces-four-abstracts-accepted-for-presentation-at-the-2024-san-antonio-breast-cancer-symposium 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/major-milestone-for-uq-spin-out-s-promising-mnd-drug 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/correcting-and-replacing-maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/year-in-review-chronic-lymphocytic-leukemia 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/syntara-announces-positive-interim-data-in-phase-2-study-of-snt-5505-in-myelofibrosis 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/with-promising-early-data-in-triple-negative-breast-cancer-a-new-bispecific-heats-up 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tourmaline-bio-highlights-cardiovascular-inflammation-focus-and-announces-key-clinical-and-strategic-updates-at-investor-day 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/what-s-going-on-with-recursion-pharmaceuticals-stock 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-secures-950k-private-placement-to-advance-thio-clinical-trials 2024-12-09T23:06:41+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-s-odronextamab-shows-remarkable-100-response-rate-in-lymphoma 2024-12-09T22:56:01+00:00 weekly 0.7 https://trial.medpath.com/news/longest-follow-up-data-reported-for-kites-tecartus-car-t-cell-therapy-at-ash-2024 2024-12-09T22:47:26+00:00 weekly 0.7 https://trial.medpath.com/news/ash-2024-astrazeneca-set-to-take-a-bite-out-of-follicular-lymphoma-market 2024-12-09T22:40:19+00:00 weekly 0.7 https://trial.medpath.com/news/spotlight-glow-trials-lead-to-fda-approval-of-zolbetuximab-clzb-with-chemotherapy 2024-12-09T22:15:51+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-rezdiffra-first-fatty-liver-disease-drug-explained-woman-s-world 2024-12-09T21:49:37+00:00 weekly 0.7 https://trial.medpath.com/news/sellas-stock-announces-positive-data-from-phase-2-trial-of-sls009-rttnews 2024-12-09T21:36:35+00:00 weekly 0.7 https://trial.medpath.com/news/theratechnologies-initial-efficacy-data-from-ovarian-cancer-drug-trial-shows-encouraging-results 2024-12-09T21:36:16+00:00 weekly 0.7 https://trial.medpath.com/news/krystal-biotech-provides-update-on-ema-s-ongoing-regulatory-review-of-b-vec-for 2024-12-09T21:20:32+00:00 weekly 0.7 https://trial.medpath.com/news/protagonist-reports-final-results-from-rusfertide-phase-2-revive-study-showing-durable 2024-12-09T21:19:20+00:00 weekly 0.7 https://trial.medpath.com/news/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-globenewswire 2024-12-09T21:10:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-acetadote-r-snda-stock-titan 2024-12-09T21:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/survey-titrating-trofinetide-improves-tolerability-among-rett-syndrome-patients 2024-12-09T20:58:32+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-review-donanemab-azbt-approved-for-early-symptomatic-alzheimer-disease 2024-12-09T20:54:29+00:00 weekly 0.7 https://trial.medpath.com/news/venetoclax-cladribine-improves-response-rates-in-aml-mds-cohorts-cancer-network 2024-12-09T20:39:11+00:00 weekly 0.7 https://trial.medpath.com/news/insights-on-ucb-s-commitment-to-advancing-rare-epilepsy-care-neurologylive 2024-12-09T20:16:43+00:00 weekly 0.7 https://trial.medpath.com/news/beacon-therapeutics-announces-positive-3-month-data-from-phase-2-dawn-trial-of-agtc 2024-12-09T20:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/secura-bio-presented-new-data-from-its-phase-2-primo-trial-of-copiktra-r-duvelisib-in 2024-12-09T20:07:50+00:00 weekly 0.7 https://trial.medpath.com/news/corbus-pharma-launches-phase-1-trial-for-novel-cancer-immunotherapy-crb-601 2024-12-09T19:57:35+00:00 weekly 0.7 https://trial.medpath.com/news/affimed-reports-promising-phase-1-efficacy-and-safety-data-for-afm28-in-relapsed-refractory-acute-myeloid-leukemia 2024-12-09T19:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-enrolled-in-inspiremd-s-cguardians-ii-pivotal-study-vascular-news 2024-12-09T19:28:58+00:00 weekly 0.7 https://trial.medpath.com/news/icer-potential-new-pain-medication-offers-small-savings-managed-healthcare-executive 2024-12-09T19:13:08+00:00 weekly 0.7 https://trial.medpath.com/news/deferasirox-achieves-transfusion-independence-in-mds-anemia-targeted-oncology 2024-12-09T19:04:09+00:00 weekly 0.7 https://trial.medpath.com/news/carta-healthcare-to-power-oncology-research-and-clinical-trials-with-acquisition-pr-newswire 2024-12-09T19:01:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-cancer-treatments 2024-12-09T18:56:44+00:00 weekly 0.7 https://trial.medpath.com/news/adding-chemoradiation-in-perioperative-gastric-cancer-treatment-improves-pathologic 2024-12-09T18:47:57+00:00 weekly 0.7 https://trial.medpath.com/news/endo-receives-u-s-fda-approval-of-manufacturing-facility-in-indore-india 2024-12-09T18:20:58+00:00 weekly 0.7 https://trial.medpath.com/news/adenosine-antagonists-clinical-trial-pipeline-analysis-10-globenewswire 2024-12-09T18:05:53+00:00 weekly 0.7 https://trial.medpath.com/news/eu-decision-time-for-orphans-acoramidis-garadacimab-imetelstat-plus-10-other-products 2024-12-09T17:23:33+00:00 weekly 0.7 https://trial.medpath.com/news/two-data-analyses-from-clinical-trials-show-epcoritamab-duobody-r-cd3xcd20 2024-12-09T17:07:53+00:00 weekly 0.7 https://trial.medpath.com/news/tandem-non-cryopreserved-car-t-exhibits-favorable-activity-in-advanced-dlbcl-healio 2024-12-09T16:55:25+00:00 weekly 0.7 https://trial.medpath.com/news/filling-out-the-roadmap-for-faster-drug-approvals-inventum 2024-12-09T16:43:28+00:00 weekly 0.7 https://trial.medpath.com/news/simple-hysterectomy-not-inferior-to-radical-hysterectomy-for-cervical-cancer-treatment 2024-12-09T16:25:20+00:00 weekly 0.7 https://trial.medpath.com/news/four-therapies-that-may-treat-kennedy-s-disease-brain-and-life-magazine 2024-12-09T16:24:03+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-ind-approval-to-base-therapeutics-base-edited-nk-cell-therapy-powered-by 2024-12-09T16:14:59+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-lenvatinib-plus-gefitinib-in-lenvatinib-resistant-hepatocellular-carcinomas 2024-12-09T15:43:23+00:00 weekly 0.7 https://trial.medpath.com/news/interim-update-from-vico-therapeutics-on-their-cag-targeting-drug-vo659-hdbuzz 2024-12-09T15:41:17+00:00 weekly 0.7 https://trial.medpath.com/news/high-fiber-diets-may-reduce-risk-of-gvhd-after-bone-marrow-stem-cell-transplants 2024-12-09T15:40:57+00:00 weekly 0.7 https://trial.medpath.com/news/stereotaxis-wins-approval-in-china-for-magnetic-ablation-catheter-massdevice 2024-12-09T15:35:57+00:00 weekly 0.7 https://trial.medpath.com/news/tiakis-biotech-ag-reports-clinical-phase-ib-ii-trial-globenewswire 2024-12-09T15:01:43+00:00 weekly 0.7 https://trial.medpath.com/news/modus-therapeutics-initiates-phase-ii-study-with-sevuparin-for-the-treatment-of-chronic-placera 2024-12-09T14:56:52+00:00 weekly 0.7 https://trial.medpath.com/news/rural-pharmacists-face-mounting-challenges-expert-highlights-critical-workforce-and-safety-concerns 2024-12-09T14:50:43+00:00 weekly 0.7 https://trial.medpath.com/news/bionomics-publishes-the-positive-results-from-the-phase-2-attune-study-of-bnc210-biospace 2024-12-09T14:44:29+00:00 weekly 0.7 https://trial.medpath.com/news/first-subject-dosed-in-initial-cohort-of-phase-2b-clinical-study-of-cyanvac-s-intranasal-biospace 2024-12-09T14:43:54+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-drug-succeeds-in-another-parkinson-s-trial-stat-news 2024-12-09T14:25:06+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-uptake-in-sickle-cell-stays-slow-despite-patient-interest-biopharma-dive 2024-12-09T14:20:34+00:00 weekly 0.7 https://trial.medpath.com/news/early-signs-of-efficacy-for-a-novel-drug-and-a-new-predictive-tool-to-guide-patient-care 2024-12-09T14:19:27+00:00 weekly 0.7 https://trial.medpath.com/news/relmada-halts-depression-drug-trials-shifts-focus-to-psilocybin-program-amid-review 2024-12-09T14:13:37+00:00 weekly 0.7 https://trial.medpath.com/news/woolsey-pharmaceuticals-reveals-breakthrough-findings-showing-spread-of-toxic-tdp-43 2024-12-09T14:02:49+00:00 weekly 0.7 https://trial.medpath.com/news/setpoint-medical-announces-filing-of-premarket-approval-pma-application-to-the-u-s 2024-12-09T13:55:37+00:00 weekly 0.7 https://trial.medpath.com/news/novel-combination-studied-in-hpv16-positive-relapsed-or-metastatic-head-and-neck 2024-12-09T13:49:05+00:00 weekly 0.7 https://trial.medpath.com/news/vikram-narayan-md-on-cystectomy-outcomes-in-nadofaragene-treated-patients 2024-12-09T13:39:20+00:00 weekly 0.7 https://trial.medpath.com/news/serial-ctdna-to-understand-parpi-resistance-nature-reviews-urology 2024-12-09T13:38:22+00:00 weekly 0.7 https://trial.medpath.com/news/new-uk-swiss-bilateral-funding-for-clinical-trials-to-open-in-2025-nihr 2024-12-09T13:31:38+00:00 weekly 0.7 https://trial.medpath.com/news/first-fda-approved-treatment-for-severe-frostbite-now-commercially-available-in-the-us 2024-12-09T13:25:23+00:00 weekly 0.7 https://trial.medpath.com/news/lomond-therapeutics-reports-results-from-ongoing-clinical-studies-of 2024-12-09T13:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/crinetics-breakthrough-oral-acromegaly-drug-advances-as-fda-accepts-nda-for-stock-titan 2024-12-09T13:10:03+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-parkinson-s-drug-tavapadon-shows-breakthrough-results-in-phase-3-trial-stock-titan 2024-12-09T13:09:37+00:00 weekly 0.7 https://trial.medpath.com/news/acurx-updates-phase-3-readiness-for-ibezapolstat-in-c-difficile-infection-based-on-recent 2024-12-09T13:04:30+00:00 weekly 0.7 https://trial.medpath.com/news/meiragtx-granted-fda-regenerative-medicine-advanced-therapy-globenewswire 2024-12-09T13:02:24+00:00 weekly 0.7 https://trial.medpath.com/news/artivion-granted-fda-humanitarian-device-exemption-for-the-amds-hybrid-prosthesis 2024-12-09T13:01:10+00:00 weekly 0.7 https://trial.medpath.com/news/cantex-scores-third-fda-orphan-drug-win-for-breakthrough-breast-cancer-brain 2024-12-09T12:41:15+00:00 weekly 0.7 https://trial.medpath.com/news/adc-therapeutics-zynlonta-shows-breakthrough-97-response-rate-in-lymphoma 2024-12-09T12:31:46+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-status-to-seres-infection-drug-investing-com 2024-12-09T12:29:51+00:00 weekly 0.7 https://trial.medpath.com/news/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-validation-of-pr-newswire 2024-12-09T12:18:57+00:00 weekly 0.7 https://trial.medpath.com/news/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-yahoo-finance 2024-12-09T12:15:03+00:00 weekly 0.7 https://trial.medpath.com/news/olema-pharma-s-novel-cancer-drug-op-3136-secures-fda-clearance-for-clinical-trials 2024-12-09T12:09:34+00:00 weekly 0.7 https://trial.medpath.com/news/nuvalent-appoints-grant-bogle-to-board-of-directors-citybiz 2024-12-09T12:00:50+00:00 weekly 0.7 https://trial.medpath.com/news/supriya-lifescience-gets-brazil-approval-for-mental-illness-drug-files-patent-for-heart 2024-12-09T11:48:58+00:00 weekly 0.7 https://trial.medpath.com/news/merck-announces-phase-3-keylynk-001-trial-met-primary-endpoint-of-progression-free 2024-12-09T11:47:15+00:00 weekly 0.7 https://trial.medpath.com/news/angiodynamics-receives-fda-clearance-for-the-nanoknife-r-system-for-prostate-tissue-ablation 2024-12-09T11:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-unveils-ide892-breakthrough-cancer-drug-candidate-with-promising 2024-12-09T11:09:50+00:00 weekly 0.7 https://trial.medpath.com/news/cspc-pharmaceutical-s-breast-cancer-drug-gains-approval-tipranks-com 2024-12-09T10:23:07+00:00 weekly 0.7 https://trial.medpath.com/news/rapport-therapeutics-presents-data-demonstrating-consistent-association-between-biospace 2024-12-09T10:17:11+00:00 weekly 0.7 https://trial.medpath.com/news/biomerieux-gains-fda-clearance-for-tropical-fever-test-markets-insider 2024-12-09T09:55:11+00:00 weekly 0.7 https://trial.medpath.com/news/cd40-targeted-therapies-clinical-trials-market-globenewswire 2024-12-09T09:49:40+00:00 weekly 0.7 https://trial.medpath.com/news/liquid-biopsies-emerge-as-game-changer-in-precision-oncology-testing-expert-highlights-value-based-care-impact 2024-12-09T09:18:53+00:00 weekly 0.7 https://trial.medpath.com/news/cytrill-bv-raises-eur85m-in-series-b-financing-european-biotechnology-magazine 2024-12-09T09:16:21+00:00 weekly 0.7 https://trial.medpath.com/news/hemogenyx-advances-clinical-trial-for-aml-treatment-tipranks-com 2024-12-09T07:59:26+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-accepts-gsk-s-submission-for-the-use-of-nucala-mepolizumab-in-copd-gsk 2024-12-09T07:03:41+00:00 weekly 0.7 https://trial.medpath.com/news/celltrion-gets-approval-of-omlyclo-in-canada-ked-global 2024-12-09T07:02:21+00:00 weekly 0.7 https://trial.medpath.com/news/be-biopharma-unveils-become-9-trial-and-presents-on-versatile-b-cell-medicines-platform 2024-12-09T06:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/aspc-congress-2024-ai-glp-1s-and-novel-imaging-reshape-cardiovascular-disease-prevention 2024-12-09T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-supply-chain-integration-critical-for-protocol-success-experts-emphasize 2024-12-09T05:50:38+00:00 weekly 0.7 https://trial.medpath.com/news/paradigm-raises-16m-for-phase-iii-trial-of-knee-osteoarthritis-treatment-stockhead 2024-12-09T05:47:23+00:00 weekly 0.7 https://trial.medpath.com/news/ms-pharma-becomes-partner-for-the-commercialization-of-fyb202-ustekinumab-in-eqs-news 2024-12-09T05:33:07+00:00 weekly 0.7 https://trial.medpath.com/news/fda-action-alert-ionis-lexicon-astrazeneca-daiichi-sankyo-and-more-biospace 2024-12-09T05:22:09+00:00 weekly 0.7 https://trial.medpath.com/news/evidence-mounts-for-potential-of-glp-1s-in-alzheimer-s-disease-biospace 2024-12-09T05:04:49+00:00 weekly 0.7 https://trial.medpath.com/news/syneos-health-announces-webinar-on-healthcare-innovation-and-digital-transformation-trends-for-2025 2024-12-09T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bridging-clinical-research-and-clinical-care-with-ai-aiding-pathologists-tool 2024-12-09T04:34:00+00:00 weekly 0.7 https://trial.medpath.com/news/china-medical-system-first-prescriptions-for-innovative-drug-lumeblue-r-issued-in-china 2024-12-09T04:07:50+00:00 weekly 0.7 https://trial.medpath.com/news/arcellx-s-multiple-myeloma-treatment-shows-breakthrough-97-response-rate-in-phase-2-trial 2024-12-09T04:04:45+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-disease-pipeline-drugs-2024-clinical-trials-ema-openpr-com 2024-12-09T03:49:07+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-approves-novo-holdings-16-5b-catalent-acquisition 2024-12-09T03:17:45+00:00 weekly 0.7 https://trial.medpath.com/news/odronextamab-ash-presentations-underscore-impressive-potential-in-earlier-lines-of-treatment-and-additional-types-of-lymphoma 2024-12-09T03:12:43+00:00 weekly 0.7 https://trial.medpath.com/news/sk-biopharmaceuticals-unveils-phase-3-cenobamate-results-in-northeast-asian-epilepsy 2024-12-09T02:59:42+00:00 weekly 0.7 https://trial.medpath.com/news/dr-foster-on-daratumumab-plus-lenalidomide-in-newly-diagnosed-myeloma-after-transplant 2024-12-09T02:57:45+00:00 weekly 0.7 https://trial.medpath.com/news/us-real-world-analysis-supports-clinical-benefit-of-tafasitamab-in-r-r-dlbcl-onclive 2024-12-09T02:41:36+00:00 weekly 0.7 https://trial.medpath.com/news/fs118-showcases-modest-efficacy-in-relapsed-refractory-dlbcl-onclive 2024-12-09T01:56:30+00:00 weekly 0.7 https://trial.medpath.com/news/puberty-blockers-can-a-drug-trial-solve-the-big-debate-bbc 2024-12-09T01:35:09+00:00 weekly 0.7 https://trial.medpath.com/news/disc-medicine-s-myelofibrosis-drug-shows-breakthrough-results-in-phase-1b-trial-with-100 2024-12-09T01:14:36+00:00 weekly 0.7 https://trial.medpath.com/news/genomic-landscape-of-circulating-tumor-dna-in-her2-low-metastatic-breast-cancer-nature 2024-12-09T01:08:28+00:00 weekly 0.7 https://trial.medpath.com/news/maintenance-teclistamab-yields-preliminary-activity-in-ndmm-cancer-network 2024-12-09T00:47:19+00:00 weekly 0.7 https://trial.medpath.com/news/agios-phase-3-trial-breakthrough-mitapivat-shows-3x-better-results-for-thalassemia-treatment 2024-12-09T00:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-s-memorable-moments-of-2024-c-en-american-chemical-society 2024-12-09T00:29:25+00:00 weekly 0.7 https://trial.medpath.com/news/actinogen-medical-expands-alzheimer-s-drug-trial-to-us 2024-12-09T00:27:44+00:00 weekly 0.7 https://trial.medpath.com/news/innovent-presents-updated-data-from-innovative-anti-cldn18-2-adc-ibi343-phase-1 2024-12-09T00:15:03+00:00 weekly 0.7 https://trial.medpath.com/news/key-fda-approvals-in-2024-c-en 2024-12-09T00:07:42+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-agonists-market-2034-clinical-trials-ema-pdma-fda-approvals-target-population-companies-delveinsight 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aptose-clinical-data-featured-in-poster-presentation-at-the-2024-ash-annual-meeting-support-tuspetinib-triple-drug-therapy-for-newly-diagnosed-aml 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/iopofosine-i-131-shows-promising-results-in-previously-treated-waldenstrom-macroglobulinemia-patients 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/endometriosis-research-faces-funding-hurdles-despite-affecting-10-of-women-globally 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/promising-results-for-disitamab-vedotin-plus-toripalimab-in-locally-advanced-or-metastatic-urothelial-carcinoma 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/batten-disease-research-updates-with-dr-ineka-whiteman 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/anlotinib-plus-chemotherapy-as-a-first-line-treatment-for-gastrointestinal-cancer-patients-with 2024-12-08T23:35:10+00:00 weekly 0.7 https://trial.medpath.com/news/zilovertamab-vedotin-r-chp-elicits-high-complete-response-rate-in-dlbcl 2024-12-08T23:32:27+00:00 weekly 0.7 https://trial.medpath.com/news/molecular-partners-presents-clinical-data-supporting-its-ongoing-mp0533-study-quantisnow 2024-12-08T23:12:09+00:00 weekly 0.7 https://trial.medpath.com/news/aes-poster-provides-safety-insights-to-antiseizure-medication-fenfluramine-neurologylive 2024-12-08T23:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-presents-positive-long-term-data-on-casgevytm-exagamglogene-autotemcel-at 2024-12-08T23:03:41+00:00 weekly 0.7 https://trial.medpath.com/news/dr-mauz-koerholz-on-the-role-of-pembrolizumab-in-younger-patients-with-low-risk 2024-12-08T23:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/positive-efficacy-and-safety-outcomes-result-from-second-line-liso-cel-in-lbcl 2024-12-08T22:47:30+00:00 weekly 0.7 https://trial.medpath.com/news/navtemadlin-monotherapy-shows-improvements-in-hallmarks-of-r-r-myelofibrosis 2024-12-08T22:37:20+00:00 weekly 0.7 https://trial.medpath.com/news/novel-ptsd-treatment-improved-symptom-severity-in-phase-iib-trial-medpage-today 2024-12-08T22:17:32+00:00 weekly 0.7 https://trial.medpath.com/news/preventing-vocs-in-people-with-sickle-cell-disease-with-exa-cel-gene-editing-therapy 2024-12-08T21:47:03+00:00 weekly 0.7 https://trial.medpath.com/news/asciminib-continues-to-best-soc-tkis-as-secondary-end-points-of-asc4first-trial-are-met 2024-12-08T21:26:36+00:00 weekly 0.7 https://trial.medpath.com/news/brexu-cel-displays-comparable-efficacy-across-age-groups-in-relapsed-refractory-b-all 2024-12-08T21:26:34+00:00 weekly 0.7 https://trial.medpath.com/news/olverembatinib-may-be-effective-in-second-line-for-cp-cml-onclive 2024-12-08T21:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/beam-therapeutics-presents-new-non-human-primate-nhp-data-demonstrating-proof-of 2024-12-08T20:57:54+00:00 weekly 0.7 https://trial.medpath.com/news/new-clinical-trial-hopes-to-find-gold-standard-for-staging-lobular-breast-cancer 2024-12-08T20:30:15+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-cancer-drug-achieves-100-complete-response-rate-in-phase-2-lymphoma-trial 2024-12-08T20:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/dr-kaddoura-on-genomic-determinants-of-outcomes-in-igh-ccnd1-myeloma-treated-onclive 2024-12-08T20:10:48+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-reports-positive-results-from-amplify-phase-3-trial-tipranks-com 2024-12-08T20:02:15+00:00 weekly 0.7 https://trial.medpath.com/news/healy-center-for-als-presents-the-lalji-award-for-innovative-healing 2024-12-08T19:47:51+00:00 weekly 0.7 https://trial.medpath.com/news/conduct-phase-iii-clinical-study-on-resistant-hypertension-cdsco-panel-tells-sun 2024-12-08T18:22:17+00:00 weekly 0.7 https://trial.medpath.com/news/mitsubishi-tanabe-pharma-america-to-present-data-on-investigational-nd0612-at-the-2024 2024-12-08T17:58:22+00:00 weekly 0.7 https://trial.medpath.com/news/five-year-results-confirm-genentech-s-polivy-combination-therapy-as-new-standard-of 2024-12-08T17:53:45+00:00 weekly 0.7 https://trial.medpath.com/news/kite-presents-new-data-underscoring-curative-potential-of-yescarta-r-in-relapsed-quantisnow 2024-12-08T17:42:11+00:00 weekly 0.7 https://trial.medpath.com/news/tecvayli-r-teclistamab-cqyv-demonstrates-potential-as-frontline-combination-therapy-for 2024-12-08T17:39:46+00:00 weekly 0.7 https://trial.medpath.com/news/roswell-park-experts-report-insights-on-car-t-for-follicular-lymphoma-keynote-667 2024-12-08T17:33:15+00:00 weekly 0.7 https://trial.medpath.com/news/cogent-biosciences-announces-positive-updated-data-from-ongoing-phase-2-apex-trial 2024-12-08T17:12:10+00:00 weekly 0.7 https://trial.medpath.com/news/antibody-shows-encouraging-results-for-treating-high-risk-follicular-lymphoma-and 2024-12-08T17:01:10+00:00 weekly 0.7 https://trial.medpath.com/news/darzalex-r-daratumumab-subcutaneous-formulation-shows-51-globenewswire 2024-12-08T16:33:08+00:00 weekly 0.7 https://trial.medpath.com/news/multi-center-study-shows-education-level-income-impact-access-to-stem-cell-transplantation 2024-12-08T16:28:37+00:00 weekly 0.7 https://trial.medpath.com/news/combining-bcl-2-and-btk-inhibitors-shows-promise-in-cll-dana-farber-cancer-institute 2024-12-08T16:17:47+00:00 weekly 0.7 https://trial.medpath.com/news/fixed-duration-calquence-plus-venetoclax-demonstrated-superior-pfs-vs-standard-of-care 2024-12-08T16:06:17+00:00 weekly 0.7 https://trial.medpath.com/news/studies-highlight-progress-in-preventing-and-treating-blood-cancers-and-pre-cancerous-conditions 2024-12-08T16:04:54+00:00 weekly 0.7 https://trial.medpath.com/news/lymphoma-immunotherapy-enhanced-by-enzyme-inhibitor-in-preclinical-model-prompting 2024-12-08T15:16:04+00:00 weekly 0.7 https://trial.medpath.com/news/maxx-orthopedics-announces-fda-clearance-of-medial-congruent-insert-for-tka-system 2024-12-08T15:14:08+00:00 weekly 0.7 https://trial.medpath.com/news/dr-jurczak-on-the-efficacy-and-safety-of-nemtabrutinib-in-r-r-follicular-lymphoma 2024-12-08T15:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/hydroxyurea-shows-clinical-benefit-in-hbsc-misses-the-mark-on-safety-hcplive 2024-12-08T14:31:59+00:00 weekly 0.7 https://trial.medpath.com/news/abbisko-cayman-reports-promising-cgvhd-drug-results-markets-insider 2024-12-08T14:31:53+00:00 weekly 0.7 https://trial.medpath.com/news/countdown-to-neo-brain-computer-interface-clinical-trial-in-china 2024-12-08T14:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/covid-19-vaccination-effective-in-preventing-long-covid-in-young-people 2024-12-08T14:10:06+00:00 weekly 0.7 https://trial.medpath.com/news/is-your-mind-ready-to-consider-investing-in-psychedelics-stocks 2024-12-08T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/ppbt-stock-surges-150-on-superior-efficacy-of-pdac-combo-therapy 2024-12-08T11:55:36+00:00 weekly 0.7 https://trial.medpath.com/news/commonly-prescribed-drugs-increase-dementia-risk-study-finds-surrey-live 2024-12-08T11:14:17+00:00 weekly 0.7 https://trial.medpath.com/news/siamak-daneshmand-md-on-safety-tolerability-data-from-sunrise-1-urology-times 2024-12-08T11:03:57+00:00 weekly 0.7 https://trial.medpath.com/news/ash-expert-axi-cel-treatment-causes-decreased-incidence-severity-of-toxicities-in-large 2024-12-08T10:54:23+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-pharmaceuticals-releases-positive-phase-3-trial-data-for-poze-cemdi 2024-12-08T10:23:03+00:00 weekly 0.7 https://trial.medpath.com/news/ash-novo-s-etavopivat-for-sickle-cell-disease-cuts-voc-rates-in-half 2024-12-08T09:58:31+00:00 weekly 0.7 https://trial.medpath.com/news/biden-administration-s-access-model-offers-hope-for-cell-and-gene-therapies-forbes 2024-12-08T08:17:55+00:00 weekly 0.7 https://trial.medpath.com/news/receiving-asct-after-first-cr-may-improve-certain-outcomes-in-aml 2024-12-08T07:23:08+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-advances-a-drug-for-a-rare-platelet-destroying-disease-stat-news 2024-12-08T05:21:36+00:00 weekly 0.7 https://trial.medpath.com/news/ketogenic-diet-and-b-hydroxybutyrate-may-enhance-car-t-cell-therapy-efficacy 2024-12-08T04:55:26+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-report-new-opportunities-to-improve-quality-of-life-for-people-with-pr-newswire 2024-12-08T04:31:56+00:00 weekly 0.7 https://trial.medpath.com/news/oral-revumenib-based-combo-produces-responses-in-r-r-aml-onclive 2024-12-08T03:14:48+00:00 weekly 0.7 https://trial.medpath.com/news/scitech-development-welcomes-john-chapman-to-the-strategic-advisory-board-as-senior 2024-12-08T02:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/promising-results-for-novel-triplet-therapy-in-high-risk-chronic-lymphocytic-leukemia 2024-12-08T01:51:07+00:00 weekly 0.7 https://trial.medpath.com/news/program-targets-poverty-to-improve-childhood-cancer-treatment 2024-12-08T00:42:09+00:00 weekly 0.7 https://trial.medpath.com/news/investigational-epcoritamab-duobody-r-cd3xcd20-combination-therapy-shows-high 2024-12-08T00:39:32+00:00 weekly 0.7 https://trial.medpath.com/news/industry-updates-from-floretina-icoor-2024-ophthalmology-times-europe 2024-12-08T00:26:22+00:00 weekly 0.7 https://trial.medpath.com/news/novel-combination-of-pozelimab-and-cemdisiran-poze-cemdi-achieved-greater-control 2024-12-08T00:06:29+00:00 weekly 0.7 https://trial.medpath.com/news/news-and-events-aviceda-therapeutics 2024-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adaptive-biotechnologies-announces-new-data-at-the-66th-ash-globenewswire 2024-12-07T23:35:57+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-uganda-makes-major-advances-new-vision-official 2024-12-07T23:34:19+00:00 weekly 0.7 https://trial.medpath.com/news/galapagos-announces-encouraging-new-results-from-ongoing-phase-1-2-study-of-cd19 2024-12-07T23:20:40+00:00 weekly 0.7 https://trial.medpath.com/news/tandem-cd20-cd19-car-zamto-cel-shows-promise-in-dlbcl-cgtlive-r 2024-12-07T21:18:49+00:00 weekly 0.7 https://trial.medpath.com/news/blincyto-r-blinatumomab-added-to-chemotherapy-significantly-amgen 2024-12-07T21:11:08+00:00 weekly 0.7 https://trial.medpath.com/news/rapcabtagene-autoleucel-shows-promise-for-dlbcl-in-updated-phase-2-data-cgtlive-r 2024-12-07T20:18:38+00:00 weekly 0.7 https://trial.medpath.com/news/uk-approves-pfizer-biontech-covid-19-vaccine-first-in-the-world-abs-cbn-news 2024-12-07T19:54:34+00:00 weekly 0.7 https://trial.medpath.com/news/commands-trial-shows-impact-of-luspatercept-on-rbc-transfusion-burden-in-lr-mds 2024-12-07T19:38:32+00:00 weekly 0.7 https://trial.medpath.com/news/reliev2-cm-study-launched-dose-finding-portion-of-anqur-underway-anavex-submits 2024-12-07T18:14:07+00:00 weekly 0.7 https://trial.medpath.com/news/sickle-cell-breakthrough-base-editing-success-mirage-news 2024-12-07T17:53:03+00:00 weekly 0.7 https://trial.medpath.com/news/updated-results-of-phase-3-allele-study-presented-at-66th-american-society-of-pr-newswire 2024-12-07T17:45:34+00:00 weekly 0.7 https://trial.medpath.com/news/latest-advances-in-aml-treatment-highlighted-at-ash-2024-annual-meeting 2024-12-07T17:43:00+00:00 weekly 0.7 https://trial.medpath.com/news/talazoparib-plus-enzalutamide-versus-olaparib-plus-abiraterone-acetate-and-niraparib-nature 2024-12-07T17:38:01+00:00 weekly 0.7 https://trial.medpath.com/news/roswell-park-study-reveals-how-venetoclax-boosts-immune-response-to-car-t-for 2024-12-07T17:33:58+00:00 weekly 0.7 https://trial.medpath.com/news/blueprint-medicines-continued-leadership-in-redefining-the-standard-of-care-in-systemic 2024-12-07T17:33:09+00:00 weekly 0.7 https://trial.medpath.com/news/valley-doctor-receives-grant-to-help-fight-pediatric-cancer-abc30-fresno 2024-12-07T17:15:34+00:00 weekly 0.7 https://trial.medpath.com/news/nektar-s-nktr-255-achieves-breakthrough-73-response-rate-in-lymphoma-trial 2024-12-07T17:15:02+00:00 weekly 0.7 https://trial.medpath.com/news/eltrombopag-improves-outcomes-in-kids-with-newly-diagnosed-itp-medpage-today 2024-12-07T17:00:07+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-data-from-the-ongoing-hibiscus-study-shows-promise-that-investigational-morningstar 2024-12-07T16:55:48+00:00 weekly 0.7 https://trial.medpath.com/news/beam-therapeutics-announces-new-data-from-beacon-phase-1-2-clinical-trial-yahoo-finance 2024-12-07T16:47:04+00:00 weekly 0.7 https://trial.medpath.com/news/bioage-shares-tumble-after-decision-to-halt-obesity-drug-study-biopharma-dive 2024-12-07T16:37:40+00:00 weekly 0.7 https://trial.medpath.com/news/the-latest-progress-in-the-application-of-telitacicept-in-autoimmune-diseases 2024-12-07T16:37:12+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-ash-rilzabrutinib-demonstrated-significant-globenewswire 2024-12-07T16:32:37+00:00 weekly 0.7 https://trial.medpath.com/news/global-clinical-trial-shows-improved-survival-rates-for-common-childhood-leukemia 2024-12-07T15:09:13+00:00 weekly 0.7 https://trial.medpath.com/news/dual-targeted-car-t-yields-99-response-rate-in-pediatric-all-medpage-today 2024-12-07T15:01:21+00:00 weekly 0.7 https://trial.medpath.com/news/cdsco-waives-local-clinical-trials-for-new-drugs-approved-in-the-us-the-hindu 2024-12-07T14:58:56+00:00 weekly 0.7 https://trial.medpath.com/news/iit-r-researchers-claim-key-insights-in-antibiotic-resistance-mechanisms-in-bacteria 2024-12-07T14:58:18+00:00 weekly 0.7 https://trial.medpath.com/news/bioage-labs-announces-discontinuation-of-strides-phase-2-globenewswire 2024-12-07T14:50:52+00:00 weekly 0.7 https://trial.medpath.com/news/india-s-eco-system-for-onco-clinical-trials-will-accelerate-best-in-class-drugs-for-patients 2024-12-07T14:31:10+00:00 weekly 0.7 https://trial.medpath.com/news/top-5-infectious-disease-news-stories-week-of-november-30-december-6-contagion-live 2024-12-07T14:10:08+00:00 weekly 0.7 https://trial.medpath.com/news/ash-2024-expert-highlights-zanubrutinib-s-sustained-efficacy-favorable-safety-profile-in-cll 2024-12-07T14:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/fda-must-disclose-more-covid-19-vaccine-records-us-judge-rules-et-healthworld 2024-12-07T13:27:19+00:00 weekly 0.7 https://trial.medpath.com/news/ratner-honored-for-career-contributions-to-nf1-research 2024-12-07T13:04:27+00:00 weekly 0.7 https://trial.medpath.com/news/incyte-announces-positive-results-from-phase-3-trial-evaluating-retifanlimab-zynyz-r-in 2024-12-07T12:34:23+00:00 weekly 0.7 https://trial.medpath.com/news/similar-persistence-rates-between-adalimumab-new-starts-switched-patients 2024-12-07T12:03:23+00:00 weekly 0.7 https://trial.medpath.com/news/curis-to-report-third-quarter-2024-financial-and-operating-results-and-host-conference 2024-12-07T11:57:31+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-game-changing-team-science-urotoday 2024-12-07T11:47:15+00:00 weekly 0.7 https://trial.medpath.com/news/going-boldly-first-person-treated-in-phase-1-clinical-trial-by-alnylam-pharmaceuticals 2024-12-07T11:35:09+00:00 weekly 0.7 https://trial.medpath.com/news/repurposed-drug-has-promising-efficacy-in-non-small-cell-lung-cancer 2024-12-07T11:32:27+00:00 weekly 0.7 https://trial.medpath.com/news/cilcare-secures-funding-to-advance-clinical-trials-for-cochlear-synaptopathy-treatment 2024-12-07T11:23:48+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-exploratory-analysis-of-post-treatment-outcomes-in-patients-with-bacillus-urotoday 2024-12-07T11:06:47+00:00 weekly 0.7 https://trial.medpath.com/news/smoking-linked-to-increased-genetic-mutations-and-faster-disease-progression-in-myelodysplastic-syndromes 2024-12-07T10:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/targeting-pik3ca-with-allosteric-inhibitors-is-promising-new-approach-in-breast-cancer 2024-12-07T09:51:18+00:00 weekly 0.7 https://trial.medpath.com/news/world-first-urine-test-for-lung-cancer-picks-out-zombie-cells 2024-12-07T08:16:50+00:00 weekly 0.7 https://trial.medpath.com/news/ngs-and-ctdna-testing-guide-treatment-selection-and-sequencing-in-mcrc-onclive 2024-12-07T07:16:47+00:00 weekly 0.7 https://trial.medpath.com/news/fred-hutch-research-shines-at-national-oncology-conference 2024-12-07T06:47:39+00:00 weekly 0.7 https://trial.medpath.com/news/the-launch-of-spima-therapeutics-pharmaceutical-executive 2024-12-07T06:31:09+00:00 weekly 0.7 https://trial.medpath.com/news/interim-analysis-highlights-long-term-safety-of-azetukalner-for-focal-epilepsy 2024-12-07T06:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-co-formulated-vibostolimab-pembrolizumab-or-co-formulated-favezelimab 2024-12-07T06:06:42+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-a-phase-i-dose-escalation-study-of-ugn-301-zalifrelimab-as-urotoday 2024-12-07T05:45:57+00:00 weekly 0.7 https://trial.medpath.com/news/ethical-considerations-for-fda-accelerated-approval-the-regulatory-review 2024-12-07T05:34:27+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-daiichi-build-cancer-drug-case-amgen-invests-1b-biopharma-dive 2024-12-07T04:15:02+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-data-on-olanzapine-and-samidorphan-highlight-maintained-schizophrenia 2024-12-07T01:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/protara-cg-oncology-tout-promising-bladder-cancer-outcomes-biospace 2024-12-07T00:46:24+00:00 weekly 0.7 https://trial.medpath.com/news/ucsf-health-experts-spotlight-advances-at-hematology-conference-uc-san-francisco 2024-12-07T00:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-study-shows-promise-for-zanubrutinib-and-venetoclax-combination-in-r-r-cll 2024-12-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/feasibility-of-simon-2-stage-futility-trials-in-early-parkinson-disease-pubmed 2024-12-06T23:56:09+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-mk-5684-003-a-phase-3-study-of-cyp11a1-inhibitor-opevesostat-versus-next 2024-12-06T22:24:30+00:00 weekly 0.7 https://trial.medpath.com/news/confirmatory-trials-us-fda-toughens-stance-on-need-for-advance-planning-due-diligence 2024-12-06T22:22:52+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-trial-shows-decreased-lung-volume-in-nsclc-heightens-pneumonitis-risk 2024-12-06T22:16:50+00:00 weekly 0.7 https://trial.medpath.com/news/dr-stearns-on-the-role-of-carboplatin-in-early-stage-tnbc-onclive 2024-12-06T22:16:41+00:00 weekly 0.7 https://trial.medpath.com/news/dr-liu-on-the-trust-ii-trial-of-taletrectinib-in-ros1-nsclc-onclive 2024-12-06T22:16:41+00:00 weekly 0.7 https://trial.medpath.com/news/enanta-pharma-to-unveil-breakthrough-rsv-pediatric-trial-results-key-phase-2-data-coming 2024-12-06T22:13:10+00:00 weekly 0.7 https://trial.medpath.com/news/drs-baljevic-and-cortes-preview-upcoming-studies-and-emerging-data-from-ash-2024 2024-12-06T22:12:26+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-clinical-progression-of-prostate-cancer-from-active-surveillance-is-predicted-by 2024-12-06T21:51:29+00:00 weekly 0.7 https://trial.medpath.com/news/patent-highlights-usp19-inhibitors-kcc2-potentiators-nrf2-inhibitors-additional-polth-inhibitors-and-more 2024-12-06T21:38:51+00:00 weekly 0.7 https://trial.medpath.com/news/iron-deficiency-anemia-therapeutics-market-size-in-the-7mm-was-around-the-globe-and-mail 2024-12-06T21:10:39+00:00 weekly 0.7 https://trial.medpath.com/news/phase-one-trial-explores-novel-immunotherapy-for-breast-cancer-news-medical 2024-12-06T21:02:56+00:00 weekly 0.7 https://trial.medpath.com/news/sana-biotechnology-stock-hits-52-week-low-at-2-29-investing-com 2024-12-06T20:57:09+00:00 weekly 0.7 https://trial.medpath.com/news/syntheticmr-receives-fda-510-k-clearance-for-symri-15-pr-newswire 2024-12-06T20:55:47+00:00 weekly 0.7 https://trial.medpath.com/news/ajmc-r-in-the-press-december-6-2024 2024-12-06T20:54:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-roundup-december-6-2024-longview-news-journal 2024-12-06T20:42:02+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-eyes-two-more-approvals-after-this-year-s-success-hiteunyuseu 2024-12-06T20:17:35+00:00 weekly 0.7 https://trial.medpath.com/news/duality-biologics-and-biontech-presented-positive-interim-data-for-investigational-b7-h3 2024-12-06T19:57:31+00:00 weekly 0.7 https://trial.medpath.com/news/can-immunotherapy-go-the-distance-in-es-ls-small-cell-lung-cancer-medpage-today 2024-12-06T19:05:39+00:00 weekly 0.7 https://trial.medpath.com/news/community-cancer-centers-face-implementation-hurdles-with-bispecific-antibody-therapies 2024-12-06T19:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/pivot-006-phase-iii-trial-of-creto-vs-surveillance-in-intermediate-risk-bladder-cancer-mark-tyson 2024-12-06T19:01:19+00:00 weekly 0.7 https://trial.medpath.com/news/biohaven-s-novel-epilepsy-drug-shows-breakthrough-safety-profile-in-clinical-trials 2024-12-06T17:57:33+00:00 weekly 0.7 https://trial.medpath.com/news/vision-rehabilitation-research-the-reporter-uab 2024-12-06T17:52:36+00:00 weekly 0.7 https://trial.medpath.com/news/new-data-supporting-a-new-precision-medicine-approach-for-als-patients-with-geneuro-s 2024-12-06T17:43:26+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-clinical-study-proves-traya-customized-regimen-delivers-3-times-better-results 2024-12-06T17:31:44+00:00 weekly 0.7 https://trial.medpath.com/news/copan-diagnostics-announces-fda-clearance-for-innovative-urine-collection-device 2024-12-06T17:28:04+00:00 weekly 0.7 https://trial.medpath.com/news/jak-inhibitor-comes-up-short-in-phase-iii-crohn-s-disease-trial-medpage-today 2024-12-06T17:25:20+00:00 weekly 0.7 https://trial.medpath.com/news/identifying-a-clinical-stage-small-molecule-yap-taz-tead-ppi-inhibitor-from-a-natural-yap-o-loop-peptide 2024-12-06T17:14:58+00:00 weekly 0.7 https://trial.medpath.com/news/phase-4-epicom-study-highlights-potential-of-cbd-in-neuropsychiatric-disorders-of 2024-12-06T17:02:13+00:00 weekly 0.7 https://trial.medpath.com/news/fostamatinib-fails-to-improve-outcomes-in-hypoxemic-covid-patients-medpage-today 2024-12-06T16:36:48+00:00 weekly 0.7 https://trial.medpath.com/news/bioarctic-doses-first-subject-in-parkinson-s-disease-therapy-trial 2024-12-06T16:01:12+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-breast-cancer-progression-drug-resistance-mirage-news 2024-12-06T15:59:52+00:00 weekly 0.7 https://trial.medpath.com/news/indapta-therapeutics-announces-clinical-study-collaboration-with-sanofi-on-multiple 2024-12-06T15:50:07+00:00 weekly 0.7 https://trial.medpath.com/news/atlas-closes-450m-biotech-fund-and-other-financing-news-pharmaphorum 2024-12-06T15:43:09+00:00 weekly 0.7 https://trial.medpath.com/news/ovarian-cancer-imaging-approach-could-enable-personalized-treatment-almost-immediately 2024-12-06T15:34:05+00:00 weekly 0.7 https://trial.medpath.com/news/chronic-pseudomonas-aeruginosa-pulmonary-infections-pipeline-insight-2024-globenewswire 2024-12-06T15:14:57+00:00 weekly 0.7 https://trial.medpath.com/news/steps-taken-by-the-government-to-promote-research-development-and-deployment-of-car-pib 2024-12-06T14:35:25+00:00 weekly 0.7 https://trial.medpath.com/news/updated-recommendation-for-universal-hepatitis-b-vaccination-in-adults-aged-19-59-years-cdc 2024-12-06T14:11:52+00:00 weekly 0.7 https://trial.medpath.com/news/jaguar-health-launches-major-clinical-trial-for-orphan-drug-crofelemer-in-short-bowel-syndrome 2024-12-06T13:55:35+00:00 weekly 0.7 https://trial.medpath.com/news/opioids-interfere-with-cancer-immunotherapy-but-these-drugs-could-help 2024-12-06T13:28:56+00:00 weekly 0.7 https://trial.medpath.com/news/verrica-s-partner-files-nda-in-japan-for-breakthrough-molluscum-treatment-stock-titan 2024-12-06T13:15:41+00:00 weekly 0.7 https://trial.medpath.com/news/fluorescent-imaging-technology-expedites-thoracic-surgery-in-lung-cancer 2024-12-06T13:05:27+00:00 weekly 0.7 https://trial.medpath.com/news/opus-genetics-inc-to-share-6-month-efficacy-and-safety-data-on-opgx-lca5 2024-12-06T12:51:06+00:00 weekly 0.7 https://trial.medpath.com/news/adc-therapeutics-to-provide-initial-data-update-on-lotis-7-clinical-trial-yahoo-finance 2024-12-06T12:42:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-novel-gene-therapy-for-fabry-disease 2024-12-06T11:48:38+00:00 weekly 0.7 https://trial.medpath.com/news/centerline-biomedical-receives-us-fda-510-k-clearance-for-its-new-iops-guidewire 2024-12-06T11:31:51+00:00 weekly 0.7 https://trial.medpath.com/news/new-therapy-helps-patients-with-tough-to-treat-bladder-cancers 2024-12-06T11:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/bostonsight-publishes-pilot-study-on-prose-scleral-lenses-as-a-drug-delivery-system-for 2024-12-06T11:06:50+00:00 weekly 0.7 https://trial.medpath.com/news/summary-report-on-authorisation-tegsedi-r-swissmedic 2024-12-06T10:28:41+00:00 weekly 0.7 https://trial.medpath.com/news/summary-report-on-authorisation-qdenga-r-swissmedic 2024-12-06T10:28:25+00:00 weekly 0.7 https://trial.medpath.com/news/hiv-aids-awareness-month-2024-looking-back-at-progress-in-gene-therapy-and-gene-editing 2024-12-06T09:17:35+00:00 weekly 0.7 https://trial.medpath.com/news/galimedix-therapeutics-initiates-phase-1-trial-of-oral-gal-101 2024-12-06T09:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/florida-cancer-specialists-research-institute-building-knowledge-and-improving-pr-newswire 2024-12-06T08:48:10+00:00 weekly 0.7 https://trial.medpath.com/news/ai-adoption-in-pharma-r-d-reaches-49-icon-survey-reveals-growing-industry-confidence 2024-12-06T08:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/finding-hope-with-antibody-drug-conjugates-in-managing-breast-cancer-cure-today 2024-12-06T08:04:07+00:00 weekly 0.7 https://trial.medpath.com/news/ugn-102-showed-promising-long-term-results-in-the-phase-3-envision-trial-potentially 2024-12-06T07:25:48+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-trial-design-for-bcg-unresponsive-nmibc-time-to-move-past-single-arm 2024-12-06T06:55:14+00:00 weekly 0.7 https://trial.medpath.com/news/innate-pharma-secures-7-9m-partnership-deal-for-lymphoma-drug-development 2024-12-06T06:48:06+00:00 weekly 0.7 https://trial.medpath.com/news/dbv-upbeat-on-allergy-patch-studies-approval-chances-allergic-living 2024-12-06T06:39:24+00:00 weekly 0.7 https://trial.medpath.com/news/new-phase-iiib-data-shows-novartis-fabhalta-r-improved-globenewswire 2024-12-06T06:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/diversity-equity-and-inclusion-guidelines-still-not-optimal-for-hiv-positive-patients 2024-12-06T06:00:01+00:00 weekly 0.7 https://trial.medpath.com/news/sulthiame-shows-promise-in-treating-obstructive-sleep-apnea-leads-ers-congress-2024-highlights 2024-12-06T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/is-it-time-to-approve-drugs-based-on-amyloid-removal-alzforum 2024-12-06T05:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-cadonilimab-improves-survival-in-advanced-cervical-cancer-oncology-nursing-news 2024-12-06T05:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-releases-draft-on-accelerated-approvals-for-drugs-biologics-bloomberg-law-news 2024-12-06T04:37:21+00:00 weekly 0.7 https://trial.medpath.com/news/pharmac-funds-new-cancer-rsv-copd-treatments-rnz-news 2024-12-06T04:36:38+00:00 weekly 0.7 https://trial.medpath.com/news/tpf-participation-department-of-transportation-commonwealth-of-pennsylvania 2024-12-06T04:36:23+00:00 weekly 0.7 https://trial.medpath.com/news/technology-revolutionizes-patient-registries-enhanced-real-world-evidence-collection-through-digital-innovation 2024-12-06T03:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/comparing-models-that-integrate-obstetric-care-and-wic-on-improved-program-enrollment 2024-12-06T03:13:54+00:00 weekly 0.7 https://trial.medpath.com/news/nuvalent-s-swot-analysis-promising-pipeline-drives-stock-outlook-investing-com 2024-12-06T03:00:22+00:00 weekly 0.7 https://trial.medpath.com/news/studies-show-more-promising-results-for-rsv-drug-nirsevimab-cidrap 2024-12-06T03:00:18+00:00 weekly 0.7 https://trial.medpath.com/news/major-treg-summit-to-showcase-latest-advances-in-autoimmune-disease-treatment-development 2024-12-06T02:36:46+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-strategies-for-rplnd-in-metastatic-testicular-seminoma-urotoday 2024-12-06T01:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/affimed-announces-acimtamig-and-allonk-r-combination-granted-globenewswire 2024-12-05T23:31:46+00:00 weekly 0.7 https://trial.medpath.com/news/medicinova-presents-study-update-and-interim-analysis-of-phase-2-3-clinical-trial-of-mn 2024-12-05T23:12:16+00:00 weekly 0.7 https://trial.medpath.com/news/kalvista-pharmaceuticals-inc-sec-10-q-report-tradingview 2024-12-05T22:36:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-ns-050-ncnp-03-rare-pediatric-disease-designation-in-duchenne-muscular-dystrophy 2024-12-05T22:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-sunrise-5-a-phase-iii-randomized-open-label-study-of-tar-200-compared 2024-12-05T22:05:40+00:00 weekly 0.7 https://trial.medpath.com/news/brief-everest-unveils-positive-results-for-kidney-drug-ever001-in-phase-1b-2a-trial 2024-12-05T21:38:27+00:00 weekly 0.7 https://trial.medpath.com/news/bcm-receives-3-5-million-to-study-telehealth-genetic-services-for-sick-underserved-newborns 2024-12-05T21:09:28+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-formulation-of-pazopanib-tablets-in-rcc-sarcoma-cancer-network 2024-12-05T20:25:26+00:00 weekly 0.7 https://trial.medpath.com/news/how-the-healy-als-platform-trial-is-helping-to-accelerate-the-pathway-to-new-als-treatments 2024-12-05T20:22:39+00:00 weekly 0.7 https://trial.medpath.com/news/research-roundup-the-latest-science-discoveries-and-breakthroughs 2024-12-05T20:04:16+00:00 weekly 0.7 https://trial.medpath.com/news/lungpacer-medical-announces-premarket-approval-for-aeropace-r-system-biospace 2024-12-05T19:53:23+00:00 weekly 0.7 https://trial.medpath.com/news/tilt-biotherapeutics-provides-update-on-international-clinical-trial-progress-with-biospace 2024-12-05T19:53:14+00:00 weekly 0.7 https://trial.medpath.com/news/nuvig-pulls-in-161m-to-make-better-immune-drugs-biopharma-dive 2024-12-05T19:53:13+00:00 weekly 0.7 https://trial.medpath.com/news/protera-therapeutics-stock-remains-buy-rated-after-promising-tara-002-phase-ii-results 2024-12-05T19:28:36+00:00 weekly 0.7 https://trial.medpath.com/news/rochester-regional-health-s-sands-constellation-heart-institute-becomes-first-u-s-site-for 2024-12-05T19:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-redefines-standard-of-care-for-frontline-advanced-endometrial-cancer 2024-12-05T19:05:47+00:00 weekly 0.7 https://trial.medpath.com/news/cytokine-tv-implantable-protein-sensors-monitor-live-inflammation 2024-12-05T19:02:53+00:00 weekly 0.7 https://trial.medpath.com/news/maat-pharma-sa-announces-first-u-s-patient-treated-at-city-of-hope-under-marketscreener 2024-12-05T19:01:51+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-tested-to-reduce-side-effect-of-half-matched-stem-cell-transplants 2024-12-05T18:46:50+00:00 weekly 0.7 https://trial.medpath.com/news/epicentrx-s-oncolytic-virus-delivered-tgfb-inhibitor-adapt-001-receives-fda-fast-track 2024-12-05T18:45:59+00:00 weekly 0.7